CONFIDENTIAL  
The information contained in this document is regarded as confidential, and may not be disclosed to another party unless such disclosure is 
required to initiate the study, to conduct study -related activities, or to comply with national, state, or local laws and regulations.  Written 
authorization from the coordinating site and sponsor is required for disclosure otherwise.  
PT-PhI-II v04.30.14  
 
 
 
Phase 2 Study of  Sym004 for Adult Patients with Recurrent 
Glioblastoma  
 
 
  
 
 
 Sponsor:  PI – Duke Cancer Institute  
 Funding Source:  Symphogen A/S  
 Protocol Source:  PI - Duke Cancer Institute  
 Duke IRB#:  Pro000 [ZIP_CODE]  
 IND#  127275  
Principal Investigator  
[INVESTIGATOR_12583], MD, FRCPC  
The Preston Robert Tisch 
Brain Tumor Center at Duke  
Room 047 Baker House  
DUMC 3624 (919) 681- 4047  
(919) 684- 6674  
[EMAIL_208]  
  Sub-Investigator(s)  
Henry Friedman, MD  
[EMAIL_209]  
 
Roger McLendon, MD  
[EMAIL_210]  
 
Katherine Peters, MD, PhD  
[EMAIL_211]  
 Dina Randazzo, DO  
[EMAIL_212]  
 Gordana Vlahovic, MD, MHS  
[EMAIL_213]  Statistician  
James E. Herndon, II, PhD  
[EMAIL_214]  
 
Lead Study Coordinator  
Woody Massey  
[EMAIL_215]  
 
Lead Regulatory Coordinator  
Elizabeth S. Miller  
Elizabeth.s.miller @duke.edu  
 Lead Data Manager  
Eric Lipp  
[EMAIL_216]  
 
Original  version:  7/9/2015   
Amended version:  03/15/201 6  
 05/13/2016   
 07/5/2017   

Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/[ADDRESS_11990] OF ABBREVIATIONS ................................................................................................. 6  
3 PROTOCOL SYNOPSIS AND RESEARCH SUMMARY  .................................................. 8  
3.1 Purpose ............................................................................................................................. 8  
3.2 Design and Procedure....................................................................................................... 8  
3.3 Selection of Subjects ........................................................................................................ 9  
3.4 Data Analysis and Statistical Considerations ................................................................. 10  
4 STUDY SCHEMA ................................................................................................................ 11  
5 BACKGROUND AND SIGNIFICANCE  ............................................................................ 12  
5.1 Study Disease ................................................................................................................. 12  
5.2 Study Agent .................................................................................................................... 12  
5.3 Study Purpose/Rationale ................................................................................................ [ADDRESS_11991]-Amendment 31 ................................................................ 14  
7.1.3  Safety Considerations ............................................................................................. 14  
7.1.4  Delayed Infusions for Scheduling Issues ................................................................ 15  
7.1.5  Concomitant Medications ....................................................................................... 15  
7.1.6  Study Drug Blinding ............................................................................................... 15  
7.1.7  Randomization ........................................................................................................ 15  
7.1.8  Quality of Life Assessments ................................................................................... 16  
7.2 Rationale for Selection of Dose, Regimen, and Treatment Duration............................. 16  
7.3 Definition of Evaluable Subjects, On Study, and End of Study .................................... 16  
7.4 Early Study Termination ................................................................................................ 16  
8 STUDY DRUG  ..................................................................................................................... 17  
8.1 Names, Classification, and Mechanism of Action ......................................................... 17  
8.2 Packaging and Labeling  ................................................................................................. 17  
8.3 Supply, Receipt, and Storage ......................................................................................... 17  
8.4 Dispensing and Preparation ............................................................................................ 17  
8.5 Compliance and Accountability ..................................................................................... 18  
8.6 Disposal and Destruction ............................................................................................... 18  
Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/[ADDRESS_11992] ELIGIBILITY ..................................................................................................... 18  
10 SCREENING AND ON- STUDY TESTS AND PROCEDURES........................................ 19  
10.1  Screening Examination ............................................................................................... 20  
10.2  Run-In Period ............................................................................................................. 20  
10.3  Treatment Period ........................................................................................................ 20  
10.4  Re-treatment Criteria (day 1 and day 15) ................................................................... [ADDRESS_11993](s) .................................................................................. 22  
10.8.1  Criteria for Early Withdrawal ................................................................................. 22  
10.8.2  Follow-up Requirements for Early Withdrawal ..................................................... 23  
10.8.3  Replacement of Early Withdrawal(s)...................................................................... 23  
10.9  Study Assessments ..................................................................................................... 23  
10.9.1  Medical History  ...................................................................................................... 23  
10.9.2  Physical Exam and Neurological Assessment ........................................................ 23  
10.9.3  Radiographic Review .............................................................................................. 23  
10.9.4  Skin Toxicity Assessments ..................................................................................... 23  
10.9.5  Correlative Assessments ......................................................................................... 23  
10.9.6  Laboratory Evaluations  ........................................................................................... 24  
10.9.7  Quality of Life Assessments ................................................................................... 24  
11 SAFETY MONITORING AND REPORTING .................................................................... 24  
11.1  Adverse Events ........................................................................................................... 24  
11.1.1  Overview of Clinical Findings and side effects ...................................................... 24  
11.1.2  Reporting of AEs .................................................................................................... 25  
11.2  Serious Adverse Events .............................................................................................. 25  
11.2.1  Reporting of SAEs to Duke Cancer Institute Safety Desk ..................................... 26  
11.2.2  Reporting to the FDA.............................................................................................. 27  
11.2.3  Safety Reporting to Symphogen Global Pharmacovigilance.................................. 27  
11.2.4  Exposure in Utero ................................................................................................... 27  
11.3  Emergency Unblinding of Investigational Treatment ................................................ 28  
11.4  Other Reportable Information .................................................................................... 28  
11.5  Special Warnings and Precautions ............................................................................. 28  
11.6  Safety Oversight Committee (SOC) ........................................................................... 28  
Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/[ADDRESS_11994] (DSMB) ............................................... 28  
12 QUALITY CONTROL AND QUALITY ASSURANCE  .................................................... 28  
12.1  Monitoring .................................................................................................................. 28  
12.2  Audits.......................................................................................................................... 28  
12.3  Data Management and Processing  .............................................................................. 29  
12.3.1  Case Report Forms (CRFs) ..................................................................................... 29  
12.3.2  Data Management Procedures and Data Verification  ............................................. 29  
12.3.3  Study Closure .......................................................................................................... 29  
13 STATISTICAL METHODS AND DATA ANALYSIS ...................................................... 30  
13.1  Analysis Sets ............................................................................................................... 30  
13.2  Patie nt Demographics and Other Baseline Characteristics ........................................ 30  
13.3  Treatments  .................................................................................................................. 30  
13.4  Primary Objective ....................................................................................................... 30  
13.4.1  Variable  ................................................................................................................... 30  
13.4.2  Statistical Hypothesis, Model, and Method of Analysis ......................................... 30  
13.4.3  Handling of missing values, censoring, and discontinuations ................................ 30  
13.5  Secondary Objectives ................................................................................................. 31  
13.5.1  Key Secondary Objective: Safety ........................................................................... 31  
13.5.2  Other Secondary Objectives:  Response Rate and Survival ................................... 31  
13.6  Exploratory Objectives ............................................................................................... 31  
13.7  Interim Analysis ......................................................................................................... 32  
13.7.1  Interim Efficacy Analysis for 18 mg/kg Sym004 ................................................... 32  
13.7.2  Interim Efficacy Analysis for 24 mg/kg Sym004 ................................................... 32  
13.7.3  Skin Toxicity Monitoring among Patients Treated with 18 mg/kg Sym004 .......... 33  
13.7.4  Initial Toxicity Monitoring among Patients Treated with 24 mg/kg Sym004 ........ 33  
13.8  Sample Size Calculation  ............................................................................................. 34  
13.8.1  Sample Size Requirements for 18 mg/kg Sym004 ................................................. 34  
13.8.2  Sample Size Requirements for 24 mg/kg Sym004 ................................................. [ADDRESS_11995] and DCI Cancer Protocol Committee ................. 35  
14.3  Informed Consent ....................................................................................................... 35  
14.4  Study Documentation ................................................................................................. 36  
14.5  Privacy, Confidentiality, and Data Storage ................................................................ 36  
Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/2017  
 
PT-PhI-II v04.30.14  Duke Cancer Institute  Page 5 of 50 
CONFIDENTIAL  
 14.6  Data and Safety Monitoring ....................................................................................... 37  
14.7  Protocol Amendments ................................................................................................ 37  
14.8  Records Retention....................................................................................................... 37  
15 REFERENCES  ..................................................................................................................... 38  
16 APPENDICES  ...................................................................................................................... 39  
16.1  Appendix A................................................................................................................. 39  
16.2  Appendix B ................................................................................................................. 40  
 
  
Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/[ADDRESS_11996]  
DSMP   Data and Safety Monitoring Plan  
DSUR   Development Safety Update Report  
DUHS   Duke University Health System  
EGFRwt   Epi[INVESTIGATOR_12584] -Fatigue  Functional Assessment of Cancer Therapy -Fatigue (FACIT -Fatigue) subscale  
FACT -BR  Functional Assessment of Cancer Therapy -Brain  
FDA  Food and Drug Administration  
FISH   Fluorescence in situ hybridization  
GBM   Glioblastoma  
Gd-DTPA   Gadolinium -diethylene Triamine Pentaacetic Acid  
GCP   Good Clinical Practices  
GMP   Good Manufacturing Practices  
H&P   History & Physical Exam  
HRPP   Human Research Protections Program  
HRQoL   Health Related Quality of Life  
ICS  Investigational Chemotherapy Service  
IHC  Immunohistochemistry  
IND  Investigational New Drug  
IRB  Institutional Research Board  
IV (or iv)   Intravenously  
KPS  K arnofsky Performance Status  
MAb   Monoclonal An tibody  
mCRC   Metastatic Colorectal Cancer  
MedDRA     Medical Dictionary for Regulatory Activities  
MG  Malignant Glioma  
Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/2017  
 
PT-PhI-II v04.30.14  Duke Cancer Institute  Page 7 of 50 
CONFIDENTIAL  
 Mg  Magnesium  
mg  Milligram  
mL  Milliliter  
mM  Millimolar  
MRI  Magnetic Resonance Imaging  
NSCLC   Non -small Cell Lung Cancer  
OARC   Office of Audit, Risk, and Compliance  
OS  Overall Survival  
PD  Progressive Disease  
PFS  Progression Free Survival  
PFS6   Progression Free Survival at 6 months  
p.o.  per os/by [CONTACT_1966]/orally  
PR  Partial Response  
PRO   Patient -Reported Outcome  
PRTBTC   Preston Robert Tisch Brain Tumor Center  
PT  Prothrombin Time  
PTT  Partial Thromboplastin Time  
RDSPs   Research Data Security Plans  
RR  Response Rate  
SCCHN   Squamous Cell Carcinoma of the Head and Neck  
SD  Stable Disease  
SGOT   Serum Glutamic Oxaloacetic Transaminase  
SOC  Safety Oversight Committee  
ULN   Upper Limit of Normal  
WHO   World Health Organization  
XRT  Radiation Therapy  
  
Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/2017  
 
PT-PhI-II v04.30.14  Duke Cancer Institute  Page 8 of 50 
CONFIDENTIAL  
 3 PROTOCOL  SYNOPSIS  AND RESEARCH SUMMARY  
3.1 Purpose  
The purpose of this study is to assess the activity of Sym 004, a recombinant antibody mixture that  specifically 
binds to EGFR, in patients diagnosed with recurrent glioblastoma  whose tumor is EGFR amplified .  
 
Primary Objective : 
Assess  the activity of Sym004 in patients with recurrent glioblastoma that are either non -bevacizumab   failures  
(Cohort  1) or who have previously failed bevacizumab ( Cohort  2), in terms of 6 -month progression -free 
survival (PFS6) . 
 
Secondary Objectives:  
1. Determine the safety of Sym004 in recurrent GBM patients . 
2. Estimate  response rate (RR)  within the two cohorts of recurrent  GBM patients . 
3. Describe overall survival (OS ) within the two cohorts of recurrent GBM patients . 
 Exploratory Objective s: 
1. Assess the impact of EGFRvIII expression on efficacy  (OS and PFS)  of Sym004. 
2. Describe patient -reported quality of life outcomes . 
 
Hypothes is 
This study hypothesizes that Sym004 will have greater activity in terms of PFS6 tha n standard treatment for 
patients with  recurrent GBM.  
3.2 Design and Procedure  
This is a phase 2 study that will accrue  patients with WHO grade IV recurrent malignant glioma (glioblastoma 
or gliosarcoma) in two cohor ts to assess the efficacy of Sym 004.  Cohort 1 will include patients who are non -
bevacizumab  failures ; whereas, Cohort [ADDRESS_11997] progress ed after prior treatment with 
bevacizumab (bevacizumab -failure).  Both cohorts  will accrue simultaneously , with 36 subjects in Cohort  1 and 
25 subjects in Cohort 2 (see Section 13.8 for justification of sample size) .  All p atients will be treated with 
Sym004, a recombinant antibody mixture that specifically binds to EGFR.  For that reason, only patients whose 
tumor is determined to be EGFR -amplified (i.e. greater than 15% of cells exhibiting  > 5 copi[INVESTIGATOR_12585] ) will 
be accrued on this study.    
 
Prior to Amendment 31, approximately 25 subjects received Sym004 at 18 mg/kg intravenously every two 
weeks .  After the approval of Amendment 31, subjects who enroll on study will receive Sym004 at  24 mg/kg 
intravenously every 2 weeks .  A total  of 65 additional subjects (36 in Cohort 1 and 2 9 in Cohort 2) will be 
treated at the 24 mg/kg dose level.  In addition, subjects who enrolled at the 18 mg/kg dose and who tolerated this dose of  Sym004 well (i.e.  no skin toxicities ≥ grade 3) will have the option to increase their dose 
to 24 mg/kg upon approval of Amendment 31.  A treatment cycle will be [ADDRESS_11998] 3 -6 patients at the 24 mg/kg dose level , regardless of cohort assignment , will be  at a 
controlled rate  for initial safety monitoring.  Details concerning this  initial accrual at the 24 mg/kg dose level 
can be found in Section 13.7.4.    
 
For an exploratory objective, w e will determine EGFRvIII status at baseline for all p atients  using archival tumor 
tissue.  If a subject has more than one source of archival or frozen tissue, each source may be requested to 
determine if EGFRvIII expression has changed over time .   
Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/[ADDRESS_11999] eligibility criteria listed in this section.  
         
Inclu sion Criteria  (answer must be  YES to  all criteria listed below)  
1. Patients must have histologically confirmed diagnosis of WHO grade 4 malignant glioma and radiograph ic 
evidence of recurrence or disease progression (as defined by [CONTACT_12616] a greater than 25% 
increase in the largest bi- dimensional product of enhancement or a new enhancing lesion, or a significant 
increase in T2/FLAIR abnormality without anoth er co -morbid cause);  
2. Age ≥ 18 years;  
3. Karnofsky Performance Status  ≥ 70%;  
4. No more than 3 prior progressions;  
5. Cohort  1 only:  Non -bevacizumab  failure, i.e. either no prior bevacizumab or bevacizumab 
stable/responder, which is defined as stable for at least  [ADDRESS_12000] (AESI)  while on a bevacizumab -
containing regimen , such as : 
a. ≥ grade 3 hypertension  not controlled by [CONTACT_12617], hypertensive crisis, or hypertensive 
encephalopathy  
b. ≥ grade 3 proteinuria  that does not resolve or nephrotic syndrome  
c. Any grade GI perforation  
d. ≥ grade 3 infusion -related reaction  
e. ≥ grade 3 woun d healing complications  
f. ≥ grade 3 hemorrhage  or any grade CNS hemorrhage  or ≥ grade 2 hemoptysis  
g. Any grade arterial thromboembolic event  (e.g. myocardial infarction or cerebral infarction)  or  ≥ 
grade 3 venous thromboembolic event  
h. Any grade posterior reversible encephalopathy syndrome (PRES)  
i. ≥ grade 3 congestive heart failure  
j. ≥ grade 2  non-gastrointestinal (GI) abscesses and fistulae ; 
6. Cohort  2 only:  Prior progression on a bevacizumab -containing regimen  (defined as having 
progressed/grown through bevacizumab by [CONTACT_12618] 2 m onths of prior bevacizumab 
treatment ); 
7. Pathology consistent with EGFR -amplification of tumor  (i.e. greater than 15% of cells exhibiting  > 5 copi[INVESTIGATOR_12586] ); archival tissue may be tested for EGFR status in a separate consent ; 
8. ANC ≥ 1,000 cells/ µl, pl atelets ≥ 100,000 cells/ µl, hemoglobin ≥ 9 g/dL ; 
9. Adequate renal function as indicated by [CONTACT_716]:  
a. Serum creatinine < 1.25 times upper limit of normal or calculated creatinine clearance ≥ 50 
ml/min ; 
b. Urine dipstick for proteinuria < 2+ unless a 24- hour urine protein <1 g of protein is 
demonstrated ; 
10. Adequate liver function as indicated by [CONTACT_716]:  
a. Total bilirubin ≤ 1.6 mg/dL ; 
b. AST/ALT ≤ 2.[ADDRESS_12001] ; 
11. Magnesium ≥ 0.9 mg/dL;  
12. For subjects on corticosteroids, they must be on a stable dose for 7 days  prior to anticipated start of study 
drug;  
13. No evidence of > grade [ADDRESS_12002] scan;  
14. Signed informed consent approved by  [CONTACT_12619] ; 
15. If the patient is a sexually active fe male of child bearing potential whose partner is male, or if the pa tient 
is a sexually active male  whose partner is a female of child bearing potential, the patient must agree to 
use appropriate contraceptive measures for the duration of the treatment of the tumor and for [ADDRESS_12003] within 48 hours of starting study treatment ; 
Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/[ADDRESS_12004] agree to use a medically acceptable contraceptive method (allowed methods 
of birth control include vasectomy or condom with spermicide) during the trial and for a period of at least  
[ADDRESS_12005] administration of trial drugs.  
 
Exclusion Criteria (answer must be NO to  all criteria listed below) : 
1. Pregnancy or breastfeeding;  
2. Prior treatment with EGFR -target ed therapy, including, but not limited to, the following examples:  
Gilotrif® (afatinib),Tarceva® (erlotinib), Erbitux® (cetuximab), Iressa™ (gefitinib), Vectibix® (panitumumab), Caprelsa® (vandetanib), Tykerb® (lapatinib), CDX110, D2C7- immunotoxin);   
3. Active infection requiring intravenous antibiotics within  7 days before enrollment;  
4. Prior, unrelated malignancy requiring curent active treatment with the exception of cervical carcinoma in 
situ and adequately treated basal cell or squamous cell carcinoma of the skin ; 
5. Less than [ADDRESS_12006] 4 weeks apart  or histo pathologic confirmation ; 
6. Treated with immunotherapeutic agents, vaccines, or M ab therapy within 4 weeks before enrollment, 
unless the patient has recovered from the expected toxic effects of such therapy ; 
7. Treated with alkylating agents within 4 weeks ( 6 weeks for nitrosoureas ) before enrollment or treated 
within 1 week before enrollment with daily or metronomic chemotherapy, unless the patient has recovered from the expected toxic effects of such therapy  to their baseline or to grade 1 ; 
8. Prior treatment  (non-alkylating agents) within 2 weeks before enrollment , unless  the patient has 
recovered from the expected toxic effects of such therapy ;  
9. Known hypersensitivity reactions to any of the components of Sym004 ; 
10. Known  current  drug abuse or alcohol abuse ; 
11. Known  Human Immunodeficiency Virus (HIV), Hepatitis B, or Hepatitis C infection. Testing is not required 
as part of this study.  
3.4 Data Analysis and Statistical Considerations  
Kaplan -Meier curves will be generated to describe the PFS  and OS experience of patients enrolled on this 
protocol within each cohort  and dose level .  Progression -free survival (PFS) is defined as the time interval 
between initiation of protocol treatment and either disease progression or death.  If the patient is alive and progression -free, P FS will be censored at the date last known alive.  Overall survival (OS) is defined as the time 
interval between initiation of protocol treatment and death, or date of last follow -up if alive.  Estimates with 
confidence intervals will be generated for medi an PFS  and OS, as well as [ADDRESS_12007] 
year (2, 4, 6, etc..) and [ADDRESS_12008] 2 years (6,  12, 18, 24)  from the time the subject 
goes on  study . 
 
Radiographic response rate will be estimated as the proportion of treated patients with a complete or partial 
response  (see Appendix B) .  An exact binomial confidence interval will be generated.  
 For each type of toxicity, the maximum grade experienced by [CONTACT_12620] .  Two adverse experience tabulations will be generated, one 
that includes all toxicities regardless of attribution, and one that includes only toxicities that are possibly, 
probably, and definitely related to Sym0 04 treatment.  
 Cox proportional hazards model will be used to examine the association between EGFRvIII expression and PFS  
and OS. 
 
At the 18 mg/kg dose level, interim analyses will be conducted after [ADDRESS_12009] 
been treat ed with Sym004.  These interim analyses will focus on the prevalence of skin toxicities . 
 
With each cohort of the study at the 24 mg/kg dose level, the study is designed as a two -stage study to assess 
6-month PFS.  After the initial stage, interim futility analyses will be conducted.
Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/2017  
 
PT-PhI-II v04.30.14  Duke Cancer Institute  Page 11 of 50 
CONFIDENTIAL  
 4 STUDY SCHEMA  
 
 
 
 
 
 
 
 
 
 Cohort 1:  Patients diagnosed  with 
WHO grade IV recurrent MG who are 
non-bevacizumab failures   
Cohort  2: Patients diagnosed with WHO 
grade IV recurrent MG who have failed 
treatment with  bevacizumab  Sym004 :  18 
mg/kg IV every 
two weeks .  
Following Amendment 
31, increased to 24 mg/kg,  
provided 
tolerability is 
demonstrated.
 CR, PR, SD  
PD, Toxicity  
 Continue on Sym004 
until complete planned 
treatment regimen, PD 
or unacceptable 
toxicity.  
Discontinue protocol 
treatment  Follow 1 year  
  1 year  
 
Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/2017  
 
PT-PhI-II v04.30.14  Duke Cancer Institute  Page 12 of 50 
CONFIDENTIAL  
 5 BACKGROUND AND SIGNIFICANCE  
5.1 Study Disease  
There is an unmet clinical need for the therapy of malignant gliomas with a median survival of <[ADDRESS_12010] of care is radiation therapy with daily temozolomide followed 
by 6 cycles of temozolomide.1   
 
Glioblastoma (GBM) is a highly angiogenic, aggressive malignant primary brain cancer; it is the most common  
and aggressive type of primary brain tumor in humans.  It accounts for 52% of all primary brain tumor cases and 20% of all intracranial tumors.  The median progression -free survival for patients treated with surgery followed 
by [CONTACT_12621] [ADDRESS_12011] been tried to reduce the tumor burden, GBM 
loses sensitivity to temozolomide.5  Overall survival is not improved and tumor progression results.4  Effective 
treatment remains an unmet medical need.   
5.2 Study Agent  
Sym004 is a re combinant antibody mixture that  binds specifically to the epi[INVESTIGATOR_12587] 
(EGFR).   Sym004 contains two mouse -human chimeric IgG1 monoclonal  antibodies, futuximab and 
modotuximab , in a 1:1 ratio . Per the Investigator’s Brochure ( v. 2.0 , 22-Jan-2015 ), the antibodies bind to non -
overlappi[INVESTIGATOR_12588].   The binding i nduces a distinct mechanism of action 
that is dependent on the presence of both antibodies  and translates into a superior anti -cancer activity  
compared to monoclonal reference antibodies .  This was  demonstrated both in vitro using human cancer cell 
lines and in vivo using EGFR -dependent  tumor xenografts.  Sym004 induces highly efficient internalization of 
EGFR on cancer cells and degradation,  which results in inhibition of cancer cell growth.   Sym004 is being 
investigated for the treatment of subjects with advanced metastatic colorectal cancer (mCRC), for the treatment of recurrent or metastatic squamous cell carcinoma of head  and neck (SCCHN), for the treatment of non -small 
cell lung cancer (NSCLC), and for the  treatment of esophageal squamous cell carcinoma (ESCC) in Japanese 
subjects . 
 
Studies have shown that Sym004 is superior at inhibiting EGFR activity compared to cetuximab and/or 
panitumum ab (used as reference antibodies) in vitro  through a mechanism of action that  is dependent on 
binding of both antibodies. 
 Furthermore, the activity of Sym004 was investigated in several xenograft tumor 
models in mice  and compared to cetuximab and/or panit umumab.   In all models, Sym004 was superior or as  
efficient as these reference antibodies.  
 Five clinical trial s have been completed with Sym004 and [ADDRESS_12012] resent Symphogen Development Safety Update Report (report dated 13 Mar 2017) .  Sym004 shows 
early signs of promising activity in the trials conducted so far.  Sym004 was  shown to induce tumor shrinkage in 
subjects resistant to combin ation treatment with  platinum -based chemotherapy and cetuximab in 
recurrent/metastatic SCCHN.  The median  OS with Sym004 of around 5 months is in the range of the reported 
median OS  in less heavily pre -treated (cetuximab -naïve), platinum -resistant recurren t/metastatic SCCHN  
subjects treated with compounds such as methotrexate or cetuximab.   In subjects with mCRC and acquired 
resistance to cetuximab, Sym004 showed promising activity  as it was able to induce tumor shrinkage in about 30 -
48% of subjects including several cases of  partial response.  
5.3 Study Purpose/Rationale  
Glioblastomas (GBMs) are highly aggressive and lethal malignant brain tumors.  The human epi[INVESTIGATOR_8199] (EGFR; HER -1) is a transmembrane receptor tyrosine kinase. It is an attractive therapeutic target 
Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/2017  
 
PT-PhI-II v04.30.14  Duke Cancer Institute  Page 13 of 50 
CONFIDENTIAL  
 for based on its role as an oncogenic driver. EGFR is amplified in 35 -40% of primary GBM tumors.6,7 
Approximately 50% of EGFR -amplified GBMs express EGFRvIII,[ADDRESS_12013] invariably failed to show efficacy in W HO grade IV 
malignant glioma patients.  
 
Sym004 is a recombinant antibody mixture which binds specifically to EGFR. Sym004 contains 2 mouse -human 
chimer ic IgG1 monoclonal antibodies (M abs), futuximab and modotuximab. The antibodies bind to non -
overlappi[INVESTIGATOR_12589]. Sym004 is not only designed to block ligand 
binding, receptor activation and downstream signaling but also elicits effective removal of the EGFR receptors 
from the c ancer cell surface by [CONTACT_12622]. In addition, unlike the single 
monoclonal anti -EGFR antibodies which only mediate antibody -dependent cellular cytotoxicity (ADCC), Sym004 
mediates both ADCC and complement -mediated cytoto xicity against EGFR -positive tumor targets.  The activity of 
Sym004 was investigated in several xenograft tumor models in mice and compared to cetuximab and/or 
panitumumab. In all models, Sym004 was either superior to or as efficient as these reference ant ibodies. T hree  
clinical trials have been co mpleted  with Sym004 as a single agent in subjects with recurrent advanced solid 
tumors  (Sym004- 01, Sym004- 02, and Sym004- 06). Sym004 shows signs of promising activity in both trials 
conducted so far. Skin toxiciti es were the most frequently reported A Es, seen in 80 -97% of subjects . 
 Given the dire need for new therapi[INVESTIGATOR_12590], particularly after bevacizumab -failure, the proposed 
clinical trial is an important step in the field of neuro -oncology. To assu re that the appropriate patient population 
will be enrolled on study, only recurrent WHO grade IV malignant glioma patients with known EGFR amplification 
as defined in the eligibility criteria (at diagnosis or at recurrence) will be eligible.
 
6 OBJECTIVES AN D ENDPOINTS  
 Objective  Endpoint  Analysis  
Primary  Assess  the activity of Sym004 in 
patients with recurrent glioblastoma 
that are either non -bevacizumab  
failures  (Cohort 1) or who have 
previously failed bevacizumab 
(Cohort  2) The percentage of subjects who remain alive 
and progression free at 6 months (PFS 6) at 
each dose level  See Section 13.4  
Key Secondary  Determine the sa fety of Sym004 in 
recurrent GBM patients  The proportion of patients with grade 3, 4, or 
5 treatment -related adverse events  at each 
dose level  See Section 13.5.1  
Other Secondary  Estimate  response rate (RR)  within 
two cohorts of recurrent GBM 
patients  Proportion of treated patients with a 
complete or partial response  at each dose 
level  See Section 13.5.2  
Other Secondary  Describe  overall survival (OS)  within 
two cohorts of recurrent GBM 
patients  Median OS  at each dose level  See Section 13.5.[ADDRESS_12014] of EGFRvIII 
expression on efficacy (OS and PFS) 
of Sym004  Median OS and PFS within subgroups of 
patients defined by [CONTACT_12623] 13.6  
Exploratory  Describe patient -reported quality of 
life outcomes (PROs)  Mean change from baseline in each Patient -
Reported Outcome ( PRO ) subscale  within 
each Cohort  and dose level  See Section 13.6  
  
  
 
  
Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/2017  
 
PT-PhI-II v04.30.14  Duke Cancer Institute  Page 14 of 50 
CONFIDENTIAL  
 7 INVESTIGATIONAL PLAN  
7.1 Study D esign  
This is a phase 2 study that will accrue  patients with WHO grade IV recurrent malignant glioma (glioblastoma or 
gliosarcoma) in two cohorts to assess the efficacy of Sym004.  Cohort 1 will include patients who are non -
bevacizumab  failures ; whereas, Cohort [ADDRESS_12015] progress ed after prior treatment with 
bevacizumab (bevacizumab -failure).  Both cohorts  will accrue simultaneously , with a goal of 36 subjects in 
Cohort  1 and 25 subjects in Cohort  2 (see Section 13.8 for justification of sample size) .  All p atients will be 
treated with Sym004, a recombinant antibody mixture that specifically binds to EGFR.  For that reason, only 
patients whose tumor is determined to be EGFR -amplified will be accrued on this study.    
 
Prior to Amendment 31, approximately 25 subjects received Sym004 at 18 mg/kg intravenously every 2  weeks .  
After the approval of Amendment 31, subjects who enroll on study will receive 24 mg/kg intravenously every 2 
weeks.  A maximum of 6 5 additional subjects (36 in Cohort 1 and 2 9 in Cohort 2) will be treated at the 24 mg/kg 
dose level.   In addition, subjects who enrolled at the 18 mg/kg dose and who tolerated this dose of Sym004 well 
(i.e. no skin toxicities ≥ grade 3) will have the option to increase their dose to 24 mg/kg upon approval of 
Amendment 31.  A treatment cycle will be [ADDRESS_12016] 3 -6 patients at the 24 mg/kg dose level, regardless of cohort assignment, will be at a 
controlled rate for initial safety monitoring.  Details concerning this initi al accrual at the 24 mg/kg dose level can 
be found in Section 13.7.4. 
 For an exploratory objective, we will determine EGFRvIII status at baseline f or all patients  using archival tumor 
tissue .  If a subject has more than one source of archival or frozen tissue, each source may be requested to 
determine if EGFRvIII expression has changed over time.   
7.1.1 Dose Modification  
For subjects receiving 18 mg/kg, t he dose of Sym004 may be reduced by [CONTACT_12624], if the 
subject experiences  grade 3 -4 non -hematologic toxicities secondary to Sym004, e.g. skin toxicities, 
electrolyte disturbances, and gastrointestinal symptoms , or grade 4 neutropenia or thrombo cytopenia .  
Following the initial dose of 18 mg/kg every [ADDRESS_12017] their dose of Sym004 
reduced due to an aforementioned toxicity, then their next dose will be 1 5 mg/kg every 2 weeks .  If 
another reduction in dose is necessary, the subsequent dose will be 12 mg/kg every [ADDRESS_12018] -Amendment 31  
For subjects receiving 24 mg /kg, the dose  of Sym004 may be reduced by [CONTACT_12624], if the 
subject experiences grade 3 -4 non -hematologic toxicities secondary to Sym004, e.g. skin toxic ities, 
electrolyte disturbances, and gastrointestinal symptoms , infusion- related reactions, or grade 4 
neutropenia or thrombocytopenia.  Exceptions to this dose reduction include grade 3 nausea, vomiting, diarrhea or fatigue lasting ≤ 5 days with supportive care or grade 3 asymptomatic electrolyte 
abnormalities.  Following the initial dose of 24 mg/kg every [ADDRESS_12019] their 
dose of Sym004 reduced due to an aforementioned toxicity, then their next dose will be 18 mg/kg every 2 
weeks.  If another reduction in dose is necessary, the subsequent dose will be 15 mg/kg every 2 weeks.  If 
dose reduction is required more than two times, the patient will be removed from the study.
 
7.1.3 Safety Considerations  
According to the Sym004 Investigator’s Brochure ( v. 8.0, 13- Mar -2017 ), skin toxicities have been  the most 
frequently reported A Es.  To date ( 20 Jan 2017 ), approximately  380 subjects with solid tumors , including 
Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/2017  
 
PT-PhI-II v04.30.14  Duke Cancer Institute  Page 15 of 50 
CONFIDENTIAL  
 subjects with recurrent/metastatic SCCHN, mCRC, ESCC and NSCLC, have been treated with  Sym004 in  
weekly doses of up to 12 mg/kg and in doses every  other week of up to 18 mg/kg  in ongoing Symphogen -
sponsored studies .  Anti -EGFR related skin toxicities (including rash, pruritus, skin fissures, dry skin, 
erythema, and  paronychia) have been observed in more than 90% of subjects in the completed and 
ongo ing clinical trials.   In subjects who had previously received anti -EGFR mAb therapy, Grade 3 skin 
toxicities were frequently reported ; 50-69% of subjects at a dose of 9 or 12 mg/kg weekly (Sym004- 01 
Parts B and C and Sym004 -02) and 33.3% and 41.2% of subje cts at dose levels of 12 mg/kg and 18 mg/kg, 
respectively, every other week (Sym004 -01 Parts D and E).  
 
Other adverse events (A Es) associated with anti- EGFR mAbs, such as electrolyte disturbances  (in particular 
hypomagnesemia), mucositis, and diarrhea were  also frequently observed in the  completed and ongoing 
trials.    In clinical trials for which AE data are available  (Sym004- 01-Parts A, B, C, D, E, Sym004 -02, and EMR 
200637- 001- Part A) hypomagnesemia was reported in 54 -77% of subjects, and 0 -38% of subjec ts 
experienced Grade 3 or 4 hypomagnesemia.  In the Sym004- 01 and Sym004- 02 clinical trials, events of 
hypomagnesemia  also represented the majority of serious adverse events (SAEs) that were considered to 
be related  to Sym004 therapy.  Serious clinical comp lications of hypomagnesemia have not been 
observed.   Mucositis was observed in up to 40% of subjects, but the number of subjects experiencing 
Grade 3 mucositis was low ([ADDRESS_12020]).  Diarrhea has been reported in up to 59% of subjects; and ≤ 10% of 
subjects  experienced Grade [ADDRESS_12021] also been observed.  
 Therefore, subjects will be assessed  at each clinic visit, beginning with Cycle 1 :Day 1 5,
 for skin toxicities 
according to Duke Medicine’s “Guidelines for Management of Cutaneous Toxicity for Patients Receiving 
Epi[INVESTIGATOR_12591]” (see Appendix A ).  Patients  will be instructed to call if the rash is 
painful or interfering with daily functioning .  In all ongoing clinical trials, premedication with 
glucocorticosteroids  and antihistamines prior to Sym004 infusion is required.     Pre-medications in the 
current study are described in Section 7.1.5 below.   Supplemental  guidelines on grading and management 
of skin toxicities due to Sym004 ha ve been provided by [CONTACT_12625] “Skin Management Booklet.”  
This booklet has been used on other Sym 004 trials and has been provided as a helpful tool for providers.  
7.1.4 Delayed Infusion s for Scheduling  Issues  
A delayed infusion of Sym004, due to scheduling issues,  may be re -scheduled within the following 4  days.   
7.1.5 Concomitant Medications  
Skin toxicities will be treated according to Duke Medicine’s “Guidelines for Management of Cutaneous Toxicity for Patients Receiving Ep idermal Growth Factor Receptors ” (see Appendix A ), in conjunction with 
Symphogen’s “Skin Management Booklet” for Sym004 .  In the current study, subjects should receive the 
following premedications, according to institutional guidelines and the judgement of the treating physician:  diphenhydramine [ADDRESS_12022] dose.  P remedication should be administered for subsequent doses based 
upon clinical judgment and presence/severity of prior  need.  
 Hypomagnesaemia , mucosal inflammation, and diarrhea will be treated according to institutional 
guidelines and the treating physician’s discretion. 
7.1.6 Study Drug Blinding  
Not applicable.  
7.1.7 Randomization  
Not applicable.  
Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/2017  
 
PT-PhI-II v04.30.14  Duke Cancer Institute  Page 16 of 50 
CONFIDENTIAL  
 7.1.8 Quality of Life Assessments  
Quality of Life will be assessed using standardized and validated questionnaires.  These questionnaires 
include Functional Assessment of Cancer Therapy -Brain (FACT -BR) scale,9 Functional Assessment of Cancer 
Therapy -Fatigue (FACIT -Fatigue) subscale, version 4,10 and  Beck depression inventory  II (BDI-II).[ADDRESS_12023] progressive 
disease prior to beginning an even- numbered cycle, when HRQoL assessments are not conducted, they 
may complete these assessments at any time during the clinic visit.
 
7.2 Rationale for Selection of Dose, Regimen, and Treatment Durat ion 
Per the Sym004 Investigator’s Brochure ( v. 7.0, 10- Mar -2017) , seven  clinical trials have been conducted with 
Sym004, [ADDRESS_12024] been exposed to Sym004  thus far  in weekly doses of up to 12 mg/kg and in doses every other week 
of up to 18 mg/kg .  Results thus far indicate that the 18 mg/kg every other week dosing results in substantially 
less issues with skin toxicity  than other dosi ng/scheduling  regimens  (see Section 7.1.3 for details regarding  the 
frequency of  skin toxicities experienced with the Sym004 dosing regimens  in ongoing clinical trials ).  A total of [ADDRESS_12025] received 18 mg/kg every other week in Part E of the Sym004 -01 trial.    
 
In the current trial, interim analysis occurred after 19 patients were treated.  A fter those 19 patients were 
treated at 18 mg/kg, it was observed that only two patients experienced grade [ADDRESS_12026] previously reported that patients who experience EGFR -directed therapy side effects (e.g. skin toxicity) are 
those who  receive the greatest therapeutic benefit from this type of therapy .  Hence , it is hypothe sized that 
increasing the dos e of Sym004 to 24 mg/kg  in the current study  might increase the frequency of skin toxicity , but 
also improve the  overall  tumor response to the therapy.  Skin toxicities will continue to be managed  according to 
Duke Medicine’s “Guidelines for Management of Cutaneous Toxicity for Patients Receiving Epi[INVESTIGATOR_12592]” (see Appendix A ), along wit h pre -medications described in Section 7.1.3.  
7.3 Definition of Evaluable Subjects , On Study,  and End of Study  
Safety and efficacy analyses will include all patients who received any Sym004 treatment.  
 Patient s will be considered “on study” once they have signed the informed consent form , and will continue to be 
considered “on study” as long as they are receiving study -related treatment or are undergoing study -related 
follow -up tests and procedures.  If a patient who signs the informed consent form does not meet the eligibility 
criteria of the study, he or she will come off study as a “screen failure.”  Patients who sign informed consent,  are 
eligible to participate, and receive study -related treatment are considered enrolled in the study.  Subjects will be 
considered “off study” when they are no longer receiving study -related treatment and are no longer having 
study -related follow -up tests and procedures.  Once “off study,” subjects who are not screen failures will  be 
followed for progression (for patients who came off study prior to disease pr ogression) and survival status (all 
patients) for at least 1 year , if possible .   
7.4 Early Study Termination  
This study can be terminated at any time for any reason by [CONTACT_978] -sponsor.  If this occurs, all subjects on study 
will be notified as soon as possible.  Additional procedures and/or follow up should occur in accordance with 
Section  10.8, which describes procedures and process for p rematurely withdrawn patients.  
Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/2017  
 
PT-PhI-II v04.30.14  Duke Cancer Institute  Page 17 of 50 
CONFIDENTIAL  
 8 STUDY DRUG  
8.1 Names, Classification, and Mechanism of Action  
Sym004 is a 1:1 mixture of the 2 mouse -human chimeric immunoglobulin (Ig) G1 monoclonal antibodies  (mAbs), 
futuximab and modotuximab .  The antibodies bind to non -overlappi[INVESTIGATOR_12593].   Each antibody is  manufactured separately as an individual drug substance .  The [ADDRESS_12027] containing 5.0 mg/mL Sym004 active ingredient,  filled  in 30 
mL USP Type 1 glass vials  with a FluroTec® -coated halobutyl/butyl rubber stoppers  and secured with caps with 
flip-off seals  .  For clinical trial administration, each vial of Sym004 drug product has an extractable  volume of 30 
mL. 
 
The composition , as described in the Investigator’s Brochure  (v. 7.0, 10- Mar -2016), is presented below:  
 
Name [CONTACT_12648] (per mL)  Function  Grade  
Futuximab  2.5 mg  Active pharmaceutical  
ingredient  In-house  
Modotuximab  2.5 mg  Active pharmaceutical  
ingredient  In-house  
Inactive ingredients  
Tri-sodium citrate dehydrate  2.38 mg  Buffer component  Ph.Eur., USP  
Citric acid monohydrate  0.37 mg Buffer component  Ph.Eur., USP  
Sodium chloride  8.77 mg  Tonici ty adjustment  Ph.Eur., USP  
Sodium hydroxide  ~ 0.12 m ga pH adjustment  Ph.Eur., USP  
Polysorbate 20  0.5 mg  Stabilizer  Ph.Eur., USP  
Water for injection  q.s. 1.0 mL  Solvent  Ph.Eur., USP  
Ph. Eur=European Pharmacopoeia; U SP=[LOCATION_002] Pharmacopoeia.  
a Typi[INVESTIGATOR_12594].  
 Packaging , labeling , and distribution to site  of the Sym004 in 30 mL vials is performed at Catalent Pharma 
Solutions, [LOCATION_008] . Packaging and labeling will be in accordance with applicable local requirement and 
applicable GMP guidelines.  
8.3 Supply, Receipt, and Storage  
Sym004 will be packaged, labeled and supplied for clinical use by [CONTACT_12626] S olutions, [LOCATION_006].  Sym004 is 
intended for single use and should be stored between 2°C and 8°C (36° -46°F)  and must not be frozen.  The vial 
should be kept in the outer carton.   Sym004 will be supplied in cartons containing 10 vials.   
 
Sym004 will be filtered using an inline filter (0.2μm) during infusion. The product must be  protected from direct 
sunlight and must not be frozen.  The diluted infusion solution of Sym004  does not contain preservatives  and 
must be used within [ADDRESS_12028] be done immediately before 
the infusion is initiated, under aseptic conditions.   
8.4 Dispensing and Preparation  
Sym004 will be prepared and dispensed by [CONTACT_12627] (ICS).   The dose of 
Sym004 is dete rmined by [CONTACT_423]’s body weight prior to each infusion.   
 
Materials needed for preparation of Sym004 infusion bags:  
Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/2017  
 
PT-PhI-II v04.30.14  Duke Cancer Institute  Page 18 of 50 
CONFIDENTIAL  
 • 1000ml, 0.9% NaCl no n–PVC infusion bags (see Table below  for selection of infusion bag at different doses)  
• Sym004 vials   
• Needles  
• Syringes  
• Pre-printed drug bag labels (provided by [CONTACT_12628] )  
• Polyethylene lined tubing having the 0.2 or 0.22 μm filter as part of the path or as an extension  
 
Infusion bag containing 0.9% NaCl used for the different dose levels  
Dose Level (mg/kg)  Infusio n Bag  
12 1000 mL  
15 1000 mL  
18 1000 mL  
24 1000 mL  
 Preparation of Sym004 infusion bags:  
• Sym004 is diluted into infusion bags containing 1000 mL 0.9 % NaCl.   
• Remove the calculated volume of 0.9% NaCl from the infusion bag.  
• Gently mix the vials by [CONTACT_12629] – anticlockwise – clockwise for 10 -15 sec onds.   
• Draw the calculated amount of Sym004 from an appropriate number of the Sym004 vials and inject it into 
the bag .  
• Invert the bag slowly 3 times.  
• Label the bag with th e completed preprinted label, including the exact time of preparation.  
• After Sym004 has been diluted in 0.9% NaCl , it can be kept at room temperature for up to 8 hours .  
• Connect the tubing having the 0.2  or 0.22 μm filter as part of the path to the bag .  Filtration only occurs at 
this step of the Sym004 administration.  
• Start the infusion at 75 mL/hour .  The i nfusion rate may be doubled every 30 minutes as tolerated, at the  
investigator’s discretion.  The maximum infusion rate is not to exceed  10 mg/min (600 mg/hr) . 
8.5 Compliance and Accountability  
Drug accountability records will be maintained for all clinical trial supplies.  All empty and partially used clinical 
trial supplies will be destroyed in accordance with the institution’s requirements for a cyto toxic agent.  ICS will 
maintain detailed documentation of the number and identification of vials  which are destroyed, and copi[INVESTIGATOR_12595] d ocuments will be provided to Symphogen.  
8.[ADDRESS_12029] of inclusion and exclusion criteria.  
Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/2017  
 
PT-PhI-II v04.30.14  Duke Cancer Institute  Page 19 of 50 
CONFIDENTIAL  
 10 SCREENING AND ON -STUDY TESTS AND PROCEDURES  
 Time Points  
  Cycle 1  Cycle 2  Cycle 3  Cycle 4…   
Evaluation  Screening a Day 1  Day 15  Day 1  Day 15  Day 1  Day 15  Day 1  Day 15  End of 
Treatme nt  
Informed consent  X          
Determination of EGFR 
amplification b X          
History and complete 
physical exam, including 
full neurologic exam & 
KPS  X     X    X 
Interval history and brief 
physical exam   X c X X X  X X X  
Vital signs, including 
blood pressure  and 
weight ; calculate BMI d X X c X X X X X X X X 
CBC with differential  e X  X X X X X X X X 
CMP  + Mg  e X  X X X X X X X X 
Urinalysis  X          
Beta -HCG, if applicable, 
within [ADDRESS_12030] dose of Sym004 .  Some tests and procedures (as noted) are for a baseline only, not for eligibility.   
b Determination of EGFR amplification may be taken  from  the original pathology diagnosis  or maybe be tested from archival tissue as a 
part of screening by [CONTACT_4656]  (separate consent) .   
c Interval history with brief physical exam, vital signs, blood pressure, and weight do not need to be repeated if the screening exam and 
vitals occurred within [ADDRESS_12031] be calculated before every infusion.   
e Every 2 weeks , beginning with Cycle 1:Day 15. 
f MRIs will  be obtained every 8 weeks (i.e. every other cycle), prior to the start of the next cycle.  
g EGFRvIII expression will be determined at baseline using archival tumor tissue ; however, if a subject has more than one source of 
archival or frozen tissue, each source may be requested to determine if EGFRvIII expression  has changed over time.   EGFRvIII expression 
will be determined using IHC by [CONTACT_12630].    
h All quality of life assessments will be completed at baseline, prior to the start of every other cycle beginning with Cycle [ADDRESS_12032] progressive disease prior to beginning an even- numbered cycle, when HRQoL assessments are not 
conducted, they may complete these assess ments at any time during the clinic visit.  
i Skin toxicity will be evaluated at baseline and at each clinic visit, beginning with Cycle 1 Day 15, and patients will be instructed to call if 
the rash is painful or interfering with daily functioning.  If a rash is identified, it should be treated according to Duke Medicine’s 
“Guidelines for Management of Cutaneous Toxicity for Patients Receiving Epi[INVESTIGATOR_12591]”  (see Appendix A ). 
j Pre-medication should include diphenhydramine [ADDRESS_12033] dose.  Premedication should be administered for subsequent doses based upon clinical judgment and 
presence/severity of prior need.  
Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/[ADDRESS_12034] EGFR status in his or her medical records, EGFR and EGFRvIII status may be 
tested from that patient’s  archival biopsy.  The subject must sign a tissue screening consent before this can take 
place.  
 The screening examinations and procedures will take place within [ADDRESS_12035] s can be used as Cycle 1 Day 1 
examination s.  Pre-treatment evaluations to determine eligibility  are listed in the schema above and  include the 
following:   
• History and full physical exam, including a full neurologic assessment and KPS, two weeks prior to  starting 
treatment  
• Vital signs, including blood pressure  and weight  
• CBC with differential, CMP +Mg, Beta -HCG if appropriate (within [ADDRESS_12036] result prior to that time)  
• Urinalysis  
• Baseline MRI of the brain 2 weeks prior to  starting treatment  
• Determination of EGFRvIII from  archival tumor tissue 
 
• Skin assessment, as a baseline  measurement  
• Quality of life measurements, as a baseline  measurement  
• Determination of EGFRvIII amplification  
 
If a subject is found to be ineligible to participate in the study, minimal records regarding the subject and the reason for screen failure will be retained in the study database.  
10.[ADDRESS_12037] of evaluations in this study and their corresponding time points.  
 
Cycle 1, Day 1   
• Interval history and brief physical exam  
• Vital signs, including blood pressure and weight  (Calculate BMI)  
• Toxicity assessment (continuous throughout the study)  
• Pre-medication  
• Sym004 iv infusion  
 
Cycle 1, Day 15 
• Interval h istory and brief physical exam  
• Vital signs, including blood pressure and weight  (Calculate BMI)  
• Skin toxicity assessment  
• Toxicity assessment (continuous throughout the study)  
• Hematology including CBC/differential  
• CMP + Mg  
• Sym004 iv infusion  
 
Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/2017  
 
PT-PhI-II v04.30.14  Duke Cancer Institute  Page 21 of 50 
CONFIDENTIAL  
 Cycle 2, Day 1  +/- 4 days (and for even numbered cycles, Day 1)  (Tests or procedures should be performed prior 
to beginning the cycle .) 
• Interval h istory and  brief  physical exam  
• Vital signs, including blood pressure  and weight  (Calculate BMI)  
• Hematology including CBC/differential  
• CMP  + Mg 
• Skin toxicity assessment  
• Toxicity assessment (continuous throughout the study)  
• Sym004 iv infusion  
 
Cycle 2, Day 15 +/ - 4 days  (and for even numbered cycles, Day 15)  
• Interval h istory and brief physical exam  
• Vital signs, including blood pressure and weight  (Calculate BMI)  
• Skin toxicity assessment  
• Toxicity assessment (continuous throughout the study)  
• Hematology including CBC/differential  
• CMP + Mg  
• Sym004 iv infusion  
 
Cycle 3, Day 1 +/ - 4 days (and for odd numbered cycles, Day 1)  (Test s or procedures should be performed prior to 
beginning the cycle.)  
• Interval h istory and full physical exam, including a full neurologic assessment and KPS  
• Vital signs, including blood pressure  and weight  (Calculate BMI)  
• Hemato logy including CBC/differential   
• CMP  + Mg 
• MRI of the brain  (MRIs should be obtained  every 8 weeks (i.e. every other cycle), prior to the start of the 
next cycle .) 
• Quality of life measurements  (should be performed prior to other study -related evaluations at study visits, if 
at all possible )  
• Skin toxicity assessment  
• Toxicity assessment (continuous throughout the study)  
• Sym004 iv infusion  
 
Cycle 3, Day 15 +/ - 4 days (and for odd numbered cycles, Day 15)  
• Interval h istory and brief physical exam  
• Vital signs, including blood p ressure and weight  (Calculate BMI)  
• Toxicity assessment (continuous throughout the study)  
• Hematology including CBC/differential  
• CMP  + Mg 
• Skin toxicity assessment  
• Sym004 iv infusion  
10.4 Re-treatment Criteria  (day 1 and day 15)  
Subjects  must meet the following re -treatment criteria  prior to infusion with Sym004 , in order to receive the 
next scheduled infusion.  Dose modifications are allowed as described in Section 7.1.1. 
• ANC ≥ 1,000 cells/µl  
• Platelets ≥ 50,000 cells/µl  
• AST, bilirubin, creatinine ≤ 2.0 x upper limit of normal  
• Resolution of any grade 3 or greater toxicity felt to be possibly, probably or definitely attributable to the 
study regimen to grade 2 or lower  based on the i nvestigator ’s decision . 
 
Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/2017  
 
PT-PhI-II v04.30.14  Duke Cancer Institute  Page 22 of 50 
CONFIDENTIAL  
 If treatment with Sym004 is delayed for longer than 2 weeks due  to toxicities  (i.e. grade 3 -4 non -hematologic 
toxicities secondary to Sym004, such as skin toxicities, electrolyte disturbances, and gastrointestinal symptoms , 
or grade 4 neutropenia or thrombocytopenia), the MRI assessment that would normally occur prior to  beginning 
a new cycle or at the end of treatment will still be obtained no later than 8 + [ADDRESS_12038]’s last treatment visit, should include:  
• Interval h istory and full physical exam, including a full neurologic assessment and KPS  
• Vital signs, including blood pressure and weight  
• Hematology including CBC/differential  
• CMP  + Mg 
• MRI of the brain  
• Quality of life measurements  (should be performed prio r to other study -related evaluations at study visits, if 
at all possible ) 
• Skin toxicity assessment  
• Toxicity assessment  
 
If a subject goes off study and does not return to clinic as part of a regular study visit, not all tests listed above 
may be obtained as part of end of treatment, e.g. magnesium.   If this occurs, only the assessments that are 
reasonably obtainable will be collected as part of end of treatment.  
10.[ADDRESS_12039] dose of study drug, and also followed for any  
new and/or  unresolved serious adverse events considered related to study therapy.    Once “off study,” subjects 
will be followed for progression (for patients who came off study prior to disease progression) and survival status 
(all patients) at least [ADDRESS_12040] will be marked as “Patient Status Unknown,” along with a corresponding 
explanation, if any.  This status may also be documented on an “Off Study Form” in the  eCRF . 
10.[ADDRESS_12041](s)  
10.8.[ADDRESS_12042] from 
the study at any time based on his/her discretion.  Reasons for PI -initiated withdrawal may include, but 
are not limited to , the following:  
• Progressive disease as documented by [CONTACT_12631]  
• Pregnancy  
Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/2017  
 
PT-PhI-II v04.30.14  Duke Cancer Institute  Page 23 of 50 
CONFIDENTIAL  
 • Upon request of the subject  
• If, in the investigator’s medical judgment, further participation would be injurious to the subject’s 
health or well -being  
• Development of intolerable symptoms  
• Protocol deviation  
• Administrative reasons, such as a major violation of the clinical trial protocol  
• Non -compliance of the subject  
10.8.[ADDRESS_12043] withdraws from the study prematurely,  they will be asked to complete the 
tests /procedures that would have been conducted at their next scheduled visit , if physically possible .  
Patients will be followed for a minimum of [ADDRESS_12044] dose of study drug, and also followed for any new and/or unresolved serious adverse events considered related to study therapy.
 
10.8.3  Replacement of Early  Withdrawal (s) 
Subjects that withdraw early from the study will only be replaced if they did not begin study -related 
treatment with Sym004.   
10.[ADDRESS_12045] initial and interval medical histor ies will be obtained and documented per institutional 
guidelines , and should include an assessment of toxicities/side effects experienced by [CONTACT_423] . 
10.9.[ADDRESS_12046] at MRI visits 
(e.g. Cycle 3, Day 1).  Visits where an infusion is received  and no is MRI scheduled only include a brief 
physical, as well as vital signs and weig ht.   
10.9.3  Radiographic Review  
The RANO criteria will be used to determine progression and pseudo -progression, as defined by [CONTACT_12632]., 2010 (see Appendix B).12 
10.9.4  Skin Toxicity  Assessments  
Skin toxicity will be evaluated at each clinic visit, beginning with Cycle 1  Day 15,  and patients will be 
instructed to call if the rash is painful or interfering with daily functioning.  If a rash is identified, it should 
be treated according  to Duke Medicine’s “Guidelines for Management of Cutaneous Toxicity for Patients 
Receiving Epi[INVESTIGATOR_12591]”  (see Appendix A ), in co njunction with Symphogen’s “Skin 
Management Booklet” for Sym004 . 
10.9.5  Correlative Assessments  
We will determine EGFRvIII status as part of an  exploratory objective  looking at the efficacy of Sym004 in 
EGFRvIII positive patients .  Archival tissue will be used for this purpose; however, if a subject has more 
than one source of archival  tissue, each source  may be requested to determine if EGFRvIII status has 
changed over time.  EGFR  expression will be determined by [CONTACT_12633] . 
  
Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/[ADDRESS_12047] of each evaluation and what they include , when done  at a Duke facility, is below.  
• CBC with differential (hematocrit, hemoglobin, platelet count, white blood cell count, mean corpuscu lar volume, mean corpuscular hemoglobin, mean corpuscular hemoglobin concentration, 
NRBC  %, NRBC  CT, RDW -CV, absolute lymphocyte count, percent lymphocytes, percent monocytes, 
percent neutrophils, percent eosinophils, percent basophils, absolute monocyte count, absolute neutrophil count, absolute eosinophil count, absolute basophil count, red blood cell count)  
• CMP  + Mg (albumin, alanine aminotransferase, alkaline phosphatase , aspartate aminotransferase, 
total bilirubin  , total protein, calcium, potassium, sodium, carbon dioxide creatinine, urea nitroge n, 
glucose, chloride  + magnesium ) 
• Beta -HCG, if applicable, within [ADDRESS_12048] Operation Procedures (SOPs) . 
11.1 Adverse Events  
An adverse event (AE) is any untoward medical occurrence in a subject  receiving study drug  and which does not 
necessarily have a causal relationship with this treatment.   For this protocol, the definition of AE also includes 
worsening of any pre -existing medical condition.  An AE can therefore be any unfavorable and unintended or 
worsening sign (including an abnormal laboratory finding), symptom, or disease temporally ass ociated with the 
use of Sym004, whether or not related to use of the Sym004.   Abnormal laboratory findings without clinical 
significance (based on the PI’s judgment) should not be recorded as AEs.  But laboratory value changes that require therapy or adjus tment in prior therapy are considered adverse events.  
 
From the time the subject signs the informed consent form through the End of Study visit (as defined in Section 
10.5), all AEs must be recorded in the subject medical record and adverse events case report form.  
 
AEs will be assessed according to the CTCAE version 4.0.  If C TCAE grading does not  exist for an AE, the severity 
of the AE will be graded as mild  (1), moderate  (2), severe  (3), life -threaten ing (4), or fatal (5).  
 Attribution of AEs will be indicated as follows:  
• Definite:  The AE is clearly related to the study drug  
• Probably:  The AE is likely related to the study drug  
• Possible:  The AE may be related to  the study drug  
• Unlikely:  The AE is doubtfully related to the study drug  
• Unrelated:  The AE is clearly NOT related to the study drug  
11.1.1 Overview of Clinical Findings and side effects  
According to the Investigator’s Brochure ( v. 8.0, 13- Mar -2017 ), skin toxicities were the most frequently 
reported AEs.   To date ( 20 Jan 2017 ), approximately 380 subjects with solid tumors, including subjects 
with  recurrent/metastatic SCCHN, mCRC, ESCC and NSCLC , have been treated with  Sym004 in  weekly 
Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/2017  
 
PT-PhI-II v04.30.14  Duke Cancer Institute  Page 25 of 50 
CONFIDENTIAL  
 doses of up to 12 mg/ kg and in doses every other week of up to 18 mg/kg  in ongoing Symphogen -
sponsored studies .  Anti -EGFR related skin toxicities (including rash, pruritus, skin fissures, dry skin, 
erythema, and  paronychia) have been observed in more than 90% of subjects in t he completed and 
ongoing  clinical trials .  In subjects who had previously received anti -EGFR mAb therapy, Grade 3 skin 
toxicities were frequently reported; 50 -69% of subjects at a dose of 9 or 12 mg/kg weekly (Sym004- 01 
Parts B and C and Sym004 -02) and 33.3% and 41.2% of subjects at dose levels  of 12 mg/kg and 18 mg/kg, 
respectively, every other week (Sym004 -01 Parts D and E).  
 
Other adverse events (AEs) associated with anti- EGFR mAbs, such as electrolyte disturbances (in particular 
hypomagnesemia), mucositis, and diarrhea were also frequently observed in the completed and ongoing 
trials.   In clinical trials for which AE data are available (Sym004 -01-Parts A, B, C, D, E, Sym004 -02, and EMR 
200637- 001- Part A) , hypomagnesemia was reported in 54 -77% of subjects, and 0 -38% of subjects 
experienced Grade 3 or 4 hypomagnesemia. In the Sym004 -01 and Sym004- 02 clinical trials, events of 
hypomagnesemia also represented the majority of serious adverse events (SAEs) that were considered to 
be related to Sym004 th erapy.  Serious clinical complications of hypomagnesemia have not been 
observed.  Mucositis was observed in up to 40% of subjects, but the number of subjects experiencing Grade 3 mucositis was low ([ADDRESS_12049]).  Diarrhea has been reported in up to 59% of subjects; and ≤ 10% of 
subjects experienced Grade [ADDRESS_12050] also been observed.  
 
The expected adverse drug reactions are related to the biological mode of action of Sym004  through 
internalization and degradation of the EGFR  receptor and to infusion of a foreign protein agent (infusion-
related reactions).    
 At a minimum, the following relevant categories of adverse drug reactions are expected to  occur in 
relation to administration of Sym004:  
• Electrolyte imbalances, including hypomagnesaemia , hypocalcemia and  hypokalemia  (early and 
aggressive replacement therapy of magnesium is  emphasized ) 
• Dermatological toxicities, acneiform rash, skin drying and fissuring, and  secondary infections. 
Prophylact ic treatment is  allowed.  
• Infusion reactions of variable severity, requiring medical intervention and  potential discontinuation  
• Other adverse drug reactions cannot be excluded. Therefore, the patients must be closely  monitored 
and Sym004 should be administe red in an environment where full resuscitation  facilities are available.  
11.1.2  Reporting of AEs  
Symphogen Global Pharmacovigilance will be provided via secure email with AE listings as appropriate, in 
order for analysis to be performed for the Symphogen Development Safety Update Report ( DSUR ) (after 
Data Lock Point [ DLP]  for the report on January 20th).  
11.2 Serious Adverse Events  
An AE is considered “serious ,” if in the opi[INVESTIGATOR_871] , it results in  one of the following  outcomes : 
• Fatal  
• Life-threatening  
• Constitutes a congenital anomaly or birth defect  
• A medically significant condition (defined as an event that compromises subject safety or may require 
medical or surgical intervention to prevent one of the three outcomes above).  
• Requires i npatient hospi[INVESTIGATOR_1081]  
• Results in persistent or significant incapacity or substantial disruption to conduct normal life functions.  
Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/[ADDRESS_12051] study drug treatment  infusion)  to within 30 days following 
cessation of study drug treatment are reportable.   
 
The study team will complete  the DCI SAE Report Form and the DCI Safety Review Form , which will both 
be submitted to the DCI Safety Desk (Fax #: 919 -681- 9357 or  secure  email to [EMAIL_217] .edu ) and 
to the PI, [CONTACT_12650], MD, FRCPC  (email : annick.desjardins @duke.edu ) or her designee within 
24 hours  of knowledge of the event.  
 
The initial report for each SAE  should include at minimum  the following information:  
• protocol # and title  
• patient initials, study identification number, sex, age  or date of birth  
• date the event occurred  
• description of the SAE  
• dose level and cycle number at the time the SAE occurred  
• description of the patient’s condition  
• indication whether the patient remains on study  
• causality or causal relationship  
 
The DCI Safety Desk will track individual SAE reports into their internal tracking database and complete 
the initial processing within 2 business days of receipt.  For unanticipated study -related event(s), these w ill 
be processed within 1 business day of receipt.  
 De-identified source documentation (i.e. admission notes, discharge notes, applicable laboratory results, 
radiology/diagnostic testing results, etc.) should  be sent with the SAE Report Form , if available at the time 
of the report .  Any f ollow -up information including severity, action taken, concomitant medications, and 
outcome should be communicated to the DCI Safety Desk,  as soon as possible  using the same forms 
mentioned above.   The study team should keep a copy of the initial SAE forms submitted to the DCI safety 
desk and any SAE follow up forms for reference.  
 The DCI Safety Desk will use the information provided in the DCI SAE Report Form and the DCI Safety 
Review Form  to complete a FDA Form 3500A, and will submit it to the Duke University IRB, if it meets 
Duke IRB reporting requirements  (see below) .  
 
 
Only adverse events that the Duke Sponsor -Investigator determines to be serious, unanticipated, and 
related or possibly/probably (i.e. more likely than not) related to the research must be reported to the Duke IRB.  Those adverse events will be submitted in the electronic IRB (eIRB) system, according the 
following guidelines:  
• Report within [ADDRESS_12052]’s death that was unant icipated and more likely 
related to the research than unrelated;  
• Report within 5 business days of learning about any serious, unanticipated, and related or 
possibly/probably related adverse event;  
• Report within 10 business day of learning about any other unanticipated problem or event that was more likely related to the research than unrelated.  
• The Sponsor -Investigator must report to the FDA, in an IND safety report, any suspected adverse 
reaction that is both serious and unexpected. Before submitting this report, the sponsor needs to 
ensure that the event meets all three of the definitions contained in the requirement:  
o Suspected adverse reaction (i.e. there is a reasonable possibility that the drug caused the adverse event)  
o Serious  
o Unexpected  
Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/2017  
 
PT-PhI-II v04.30.14  Duke Cancer Institute  Page 27 of 50 
CONFIDENTIAL  
  
If the adverse event does not meet all three of the definitions, it should not be submitted as an expedited 
IND safety report.  
11.2.2  Reporting to the FDA  
All SAE’s that are possibly/probably related (i.e. there is evidence to suggest a causal relationship) and 
unexpected must be reported to the FDA as IND Safety Reports. The Sponsor -Investigator is required to 
report to the FDA all IND Safety reports in writing within 15 days (7 days for unexpected fatal or life-
threatening suspected (possibly/probably related)  adverse reaction s) per 21CFR312.32.   
 
The FDA Form 3500A can be found on the FDA website, www.fda.gov .  All other adverse events will be 
reported to the FDA in the Annual Report . 
  This will be done by [CONTACT_12634].  
11.2.[ADDRESS_12053] full responsibility for the scientific, medical and legal/regulatory conduct of the 
trial, as well as for study documentation and safe ty reporting responsibilities.  The Investigator  shall  
promptly report to S ymphogen all safety -related information obtained from the study as follows:  
 
For all expedited SAE reports (Initial or Follow -up) and any death (regardless of causality) that occurs 
while a subjec t is on study, i.e. within [ADDRESS_12054] becoming aware of the event and the study team notifying the DCI safety desk 
of the event . 
 All SAEs require that a Serious Adverse Event Report Form (either DCI Safety Desk SAE Report and Safety Review Form s or a  MedWatch Form 3500A) be completed and forwarded to Symphogen either via fax 
transmission  or secure email.  T he SAE Form must include a description narrative, inclusive of the 
investigator’s causality assessment.  
 
All non -expedited serious adverse events (SAEs) will be forwarded to Symphogen Pharmacovigilance 
within [ADDRESS_12055] Information  for Symphogen Global Pharmacovigilance  
Email Forms: [EMAIL_218]  
Drug Safety Telephone line:  908 -378- 9630 
Safety Fax line:  [ADDRESS_12056] 
becomes pregnant during the time of receiving study drug, or is found to be pregnant within 90 days of 
Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/[ADDRESS_12057] dose of study drug, Symphogen will be notified by [CONTACT_12635] 1 business day of the 
DCI Safety Desk learning of the event via fax or email and a Pregnancy Reporting Form will need to be 
complet ed. The pregnancy will be followed to term and all pregnancy information will be tracked within 
the Symphogen safety database.  
11.3 Emergency Unblinding of Investigational Treatment  
Not applicable.  
11.4 Other Reportable Information  
Not applicable.  
11.5 Special Warnings and Precautions  
Not applicable.  
11.6 Safety Oversight Committee (SOC)  
The Duke Cancer Institute SOC is responsible for annual data and safety monitoring of DUHS sponsor -investigator 
phase [ADDRESS_12058] 
(DSMB).  The primary focus of the SOC is review of safety data, toxicities and new information that may affect 
subject safety or efficacy.  Annual safety revi ews include but may not be limited to review of safety data, 
enrollment status, stoppi[INVESTIGATOR_12596], accrual, toxicities, reference literature, and interim analyses as 
provided by [CONTACT_456] -investigator.  The SOC in concert with the DCI Monitori ng Team (see Section 12.1 for 
Monitoring Team description) oversees the conduct of DUHS cance r-related, sponsor -investigator greater -than -
minimal- risk intervention studies that do not have an external monitoring plan, ensuring subject safety and that 
the p rotocol is conducted, recorded and reported in accordance with the protocol, standing operating 
procedures (SOPs), Good Clinical Practice (GCP), and applicable regulatory requirements.  
11.[ADDRESS_12059] (DSMB)  
Not applicable.  
12 QUALITY CONTROL AND QUALITY ASSURANCE  
12.1 Monitoring  
The Duke Cancer Institute ( DCI) Monitoring Team will conduct monitoring visits to ensure subject safety and to 
ensure that the protocol is conducted, recorded, and reported in accordance with the protocol, s tandard 
operating procedures, good clinical practice, and applicable regulatory requirements.  As specified in the DCI Data and Safety Monitoring Plan, the DCI Monitoring Team will conduct routine monitoring after the third 
subject is enrolled, followed by  [CONTACT_12636] 1 – [ADDRESS_12060] practice of the DCI m ay occur as per contractual agreement with Symphogen.   
 
Additional monitoring may be prompted by [CONTACT_12637], unexpected frequency of serious 
and/or unexpected toxicities, or other concerns and may be initiated upon request of DUHS and DCI leadership, 
the DCI Canc er Protocol Committee , the Safety Oversight Committee (SOC), the sponsor, the Principal 
Investigator, or the IRB.  All study documents must be made available upon request to the DCI Monitoring Team and other authorized regulatory authorities, including but  not limited to the National Institute of Health, 
National Cancer Institute, and the FDA.  Every reasonable effort will be made to maintain confidentiality during 
study monitoring.  
12.2 Audits  
The Duke School of Medicine Office of Audit, Risk, and Compliance  (OARC ) office  may conduct  confidential audits 
to evaluate compliance with the protocol and the principles of GCP.  The PI [INVESTIGATOR_12597]000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/2017  
 
PT-PhI-II v04.30.14  Duke Cancer Institute  Page 29 of 50 
CONFIDENTIAL  
 auditor(s)  direct access to all relevant documents and to allocate his/her time and the time of the study  team to 
the auditor(s) i n order to discuss findings and any relevant issues.  
 
OARC   audits are designed to protect the rights and well -being of human research subjects.  A udits may be 
routine or directed (for cause). Routine audits are selected based upon  risk metrics generally geared towards 
high subject enrollment, studies with limited oversight or monitoring, Investigator initiated Investigational Drugs or Devices, federally -funded studies, high degree of risk (based upon adverse events, type of study, or vulnerable 
populations), Phase I studies, or studies that involve Medicare populations. Directed audits occur at the directive of the IRB or an authorized Institutional Official.  
 OARC   audits examine research studies/clinical trials methodology, processes and systems to assess whether the 
research is conducted according to the protocol approved by [CONTACT_12638]. The primary purpose of the audit/review is to verify that the standards for safety of human subjects in clinical trials and the quality of  data 
produced by [CONTACT_12639]. The audit/review will serve as a quality assurance measure, 
internal to the institution. Additional goals of such audits are to detect both random and systemic errors 
occurring during the conduct of cl inical research and to emphasize “best practices” in the research/clinical trials 
environment.  
12.3 Data Management and Processing  
12.3.1  Case Report Forms (CRFs)  
The electronic CRF (eCRF) will be the primary data collection document for the study.  The CRFs will be 
updated in a timely manner following  acquisition of new source data.  Only approved study staff  (the PI, 
the research  coordinator s, the research nurses, the data management team,  and the clinical trials 
manager ) are permitted to make entries, changes, or corrections in the CRF.  
 An audit trail will be maintained automatically by [CONTACT_12640], which will be a 
[ADDRESS_12061] access based on their specific roles in  the 
protocol . 
 
Completeness of entered data will be checked automatically by [CONTACT_1624], and users will be alerted to the presence of data inconsistencies.  Additionally, the data management team and the statistical team  
will cross -reference the data  to verify accuracy.  Missing or implausible data will be highlighted for the PI 
[INVESTIGATOR_12598] (i.e. confirmation of data, correction of data, completion or confirmation 
that data is not availab le, etc.).  
 
The database will be reviewed and discussed prior to database closure, and will be closed only after 
resolution of all remaining queries.  An audit trail will be kept of all subsequent changes to the data.  
12.3.3  Study Closure  
Following completion of the studies, the PI [INVESTIGATOR_12599]:  
• Data clarification and/or resolution  
• Accounting, reconciliation, and destruction/return of used and unused study drugs  
• Review of site study records for completeness  
• Shipment of all remaining laboratory sample s to the desi gnated laboratories  
Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/[ADDRESS_12062] be approved by [CONTACT_12641].  
 With Amendment 31, the study has been modified to allow the assessment of activity of two different doses of 
Sym004:  18 mg/kg and 24 mg/kg.  With the increase to 24 mg/kg dose , we intend to treat 65 additional subjects at 
that dose level (36 in Cohort 1, and 2 9 in Cohort 2).  The maximum accrual goal for this study is the number  of 
subjects accrued before Amendment [ADDRESS_12063] deviations or medians/percentiles will summarize non -categorical variables.  
13.3 Treatments  
Within each cohort  and dose level , a frequency distribution will be generated for the number of doses of  Sym004 
administered.   In addition, the frequency of dose reduction will also be tabulated.  
13.4 Primary Objective  
The primary objective of the study is to assess the activity of Sym004 within two cohorts of  patients with 
recurrent glioblastoma  based upon PFS6:  patients who are non-bevacizumab  failures  (Cohort  1) and patients 
who have previously failed bevacizumab ( Cohort  2).  This assessment will be done at both dose levels.  
13.4.1  Variable  
The primary endpoint is PFS6 , which  is defined as the propor tion of patients who remain alive and 
progression -free 6 months after initiation of Sym004 treatment.   The use of PFS6 as an endpoint in phase 
II clinical trials is recommended by [CONTACT_12642] (2007) and Lamborn (2008) given the strong association 
between progr ession -free survival status and overall.13, [ADDRESS_12064] that will 
be conducted is provided in Section 13.8. 
 The pri mary analyses will focus on the dose group to which the patient was originally assigned.  No more 
than 2 of the patients treated initially at the 18 mg/kg dose will have their dose escalated to 24 mg/kg.  
Efficacy analyses will be generated with and without these patients to assess the impact of these patients with dose escalation on inferences . 
13.4.[ADDRESS_12065] to follow -up prior 
to their 6 -month outcome, estimates of PFS 6 will be appropriately adjusted for such censoring in the 
estimation of the outcome from the Kaplan -Meier estimator.  
Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/2017  
 
PT-PhI-II v04.30.14  Duke Cancer Institute  Page 31 of 50 
CONFIDENTIAL  
 13.5 Secondary Objectives  
Secondary objectives are to determine the safety of Sym004 in recurrent GBM patients  and to  determine 
response rate (R R) and overall survival (OS) in recurrent GBM patients .  These analyses will be generated for both 
dose levels.  
13.5.1  Key Secondary Objective : Safety  
Within each cohort  and dose level , the proportion of patients who experience grade 3, 4, or [ADDRESS_12066] their dose escalated from 18 mg/kg to 24 mg/kg will be included in toxicity summaries 
for 18 mg/kg and 24 mg/kg.  The toxicity experienced prior to dose escalation will be summarized with the other patients treated at the 18 mg/kg dose level; whereas, the toxicity experienced after dose escala tion 
will be included in the summary of adverse events associated with 24 mg/kg.  
13.5.2  Other Secondary Objectives :  Response Rate and Survival  
Within each cohort  and dose level , radiographic response rate will be estimated as the proportion of 
treated patients with a complete or partial response.  An exact binomial confidence interval will be 
generated.  
 Kaplan -Meier curves will be generated to describe the PFS  and OS experience of patients treated with 
Sym004 within each cohort  and dose level .  Progression -free survival (PFS) is defined as the time interval 
between initiation of protocol treatment and either disease progression or death.  If the patient is alive and progression -free, PFS will be censored at the date last known alive.  Overall survival (OS) is de fined as 
the time interval between initiation of protocol treatment and death, or date of last follow -up if alive.  
Estimates with confidence intervals will be generated for median PFS/OS, as well as [ADDRESS_12067] year (2, 4, 6, e tc..) and [ADDRESS_12068] 2 years (6,12, 18, 24)  from the 
time the subject goes on  study . 
 
The analyses of response rate, OS, and PFS will focus on the dose group to which the patient was originally assigned.  The impact that the few patients treated initially at the 18 mg/kg dose and subsequently with 
24 mg/kg will be assessed by [CONTACT_12643].  
13.6 Exploratory Objective s 
There are two  exploratory objectives for this study:  (1) A ssess the  impact of EGFRvIII expression on OS and PFS, 
and (2) D escribe patient -reported quality of life outcomes (PROs).   
 Within each cohort , dose level,  and EGFRvIII expression group, Kaplan- Meier curves will be used to describe 
OS/PFS and to estimate median OS/PFS.  For each cohort, C ox proportional hazards model will be used to 
examine the joint effect of dose and  EGFRvIII expression on  PFS/OS.  
 
Descrip tive statistics (e.g. means and standard deviations) will be used to summarize each quality of life subscale 
at each follow -up assessment .  These statistics will be generated for each cohort and dose level.  
Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/2017  
 
PT-PhI-II v04.30.14  Duke Cancer Institute  Page 32 of 50 
CONFIDENTIAL  
 13.7 Interim Analysis  
13.7.1  Interim Efficacy Analysis  for 18 mg/kg Sym004  
Interim analyses for efficacy will not  be conducted  given the expected rapi[INVESTIGATOR_12600]’s primary outcome.  If a two -stage design were 
conducted with PFS6 as an endpoint, accrual would be suspended for up to [ADDRESS_12069] been completed during that period of accrual suspension.  
13.7.2  Interim Efficacy Analysis for  24 mg/kg Sym004  
With Amendment 31, the design of the study will be modified.  Within each cohort, a two -stage study 
design is used to assess outcome.  The statistical properties of this design are provided in section 13.8.2.  
However, the stoppi[INVESTIGATOR_12601] c ohort are summarized below.[ADDRESS_12070] their dose escalated from 18 mg/kg to 24 mg/kg will not be considered in these interim 
efficacy analyses  for 24 mg/kg Sym004. 
  
Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/2017  
 
PT-PhI-II v04.30.14  Duke Cancer Institute  Page 33 of 50 
CONFIDENTIAL  
 Monitoring Rules  
 Cohort 1  Cohort 2  
Statistical Hypothesis  PFS6 ≤ 20% vs PFS6 ≥ 40%  PFS6 ≤ 3% vs PFS6 ≥ 20%  
Stage 1  Accrue 19 patients  Accrue 12 patients  
Criteria for Accrual to Stage 2  >3 patients who live 6+ months 
progression -free >0 patients who live 6+ months 
progression -free 
Stage 2  Accrue 17 more patients  Accrue 17 more patients  
 
13.7.3  Skin Toxicity Monitoring  among  Patients Treated with 18 mg/kg Sym004   
Interim analyses that focus on the physiologic consequences of S ym004 treatment will be conducted after  
[ADDRESS_12071] been treated with S ym004.  The goal of the interim analysis is 
to determine whether the dose of S ym004 needs to be increased or decreased.  The basis of this decision 
will partly be based upon the prevalence of ≥ Grade 3 skin toxicity  after the administration of 2 doses .  
However, other factors may contribute to this decision -making.   Accrual will be not be suspended while 
this assessment of skin toxicity is occurring.   The decision -making could result in 3 outcomes:  increase the 
dose, decrease the dose, or continue accruing at the current dose.  If a decision is made to modify the 
dose, the protocol will be appropriately amended.  
 
If the pre valence of skin toxicity is truly 30%  (Symphogen unpublished data) , then the dose of S ym004 is 
considered acceptable.  However, if the true prevalence of skin toxicity is much less or much g reater than 
30% , then the dose of S ym004 may need modification.   Observing skin toxicity in 2 or fewer  patient s or 9 
or more patients is an indication that the data concerning dosing needs to be carefully scrutinized along with other available data.  The probability of observing this extent of skin toxicity as a function of the true probability of skin toxicity is tabulated below.  
 
True Probability of 
Skin Toxicity  Probability of observing either 2 or fewer 
patients with skin toxicity, or observing 9 
or more patients with skin toxicity  
0.05  0.933  
0.1 0.705  
0.3 0.130  
0.5 0.677  
0.55  0.816  
0.6 0.912  
0.65  0.965  
 
13.7.4  Initial Toxicity Monitoring among  Patients Treated with 24 mg/kg S ym004 
Given limited experience with 24 mg/kg S ym004, the first 3 -6 patients will be slowly accrued and carefully 
monitored for unacceptable toxicity  (see Section 7.1.2). 
 The first patient , regardless of cohort , will be treated and observed for 1 cycle before the accrual of a 
second patient.  During this period of observation, the patient will receive at mi nimum 2 full doses of 
Sym004 and be followed until the end of Cycle 1 .  If the patient experienc es an unacceptable adverse 
event  (refer to Section 7.1.2) , the study  will be suspended and the patient’s experience will be discussed 
with Symphogen to determine whether patient accrual should continue.  Otherwise , 2 addi tional patients 
will be treated.  
 
Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/[ADDRESS_12072] been observed, 
the number of pat ients with unacceptabl e toxicity will be determined.  
 
• If none of the first 3 patients has an unacceptable toxic event, accrual will  continue without further 
slowed accrual.      
• If [ADDRESS_12073] 3 patients has an unacceptable toxicity, the study will remain suspended.  Results will 
be discussed with Symphogen with the expectation that accrual will  be terminated .  
• If [ADDRESS_12074] 1 cycle.  If none of 
the additional 3 patients expe riences an unacceptable toxicity, then accrual will resume without the 
requirement of staggered entry.  If 1 of these 3 patients experiences an unacceptable toxicity, the 
study will remain suspended while a discussion occurs with Symphogen to determine if accrual is 
terminated.  
 
For initial monitoring of the 24 mg/kg dose of S ym004, an unacceptable adverse event is defined as any 
grade 3, 4, or [ADDRESS_12075] their dose escalated from 18 mg/kg to 24 mg/kg will  be considered as part of this 
interim analyses of toxicity at the 24 mg/kg if they are among the first 3 (or 6) patients who receive Sym004 at the 24 mg/kg dose level.  
13.8 Sample Size Calculation  
13.8.1  Sample Size Requirements for 18 mg/kg Sym004  
The sample size requirements within each cohort of patients will be considered separately.  
 
Non-Bevacizumab Failures  (Cohort 1) :  In a recent phase 3 study among patients with recurrent 
glioblastoma, a PFS 6 rate of 19% (approximate 95% confidence interval: 12% - 30%) was observed for 
patients treated with lomustine.16  If the true PFS6 associated with SYM004 is comparable to that seen 
with lomustine or approximately 20%, there is limited interest in further investigation of SYM004 in this patient population.  However, if the true PFS6 is 40% or greater , there is interest in further investigation of 
the experimental treatment within this patient population.  With 36 patients, there is 90% power to differentiate between a PFS6 rate of 20% and 40% assuming a test conducted at the 0.1 level of 
significance  (1-tailed) .  If 11 or more patients of the 36 patients live more than 6 months without disease 
progression, the treatment will be considered worthy of further investigation in this patient population.   
 
Bevacizumab Failure  (Cohort 2) :  A recent publicatio n from the Preston Robert Tisch Brain Tumor Center 
reported a PFS6 rate of 2.3% (95% CI: 0.2, 10.4) among patients who received non -bevacizumab treatment 
after progression on bevacizumab treatment administered in the recurrent setting.17  If the true PFS6 
associated with SYM004 within this patient population is comparable to that observed in this publication or about 3%, there is limited interest in further investigation of the agent in this setting.  However, if the 
true PFS6 rate is 20 % or greater, there is interest in further clinical investigation.  With 25 patients, there 
is 90% power to differentiate between a PFS6 rate of 3% and 20% assuming a test conducted at the 0.1 
level of significance.  If 3 or more patients of the 25 live mo re than 6 months without disease progression, 
the treatment is worthy of further investigation.  
13.8.2  Sample Size Requirements for 24 mg/kg Sym004  
Prior to Amendment 31, the original goal was to accrue 61 subjects to receive 18 mg/kg S ym004, with 36 
patients in Cohort 1 and 25 in Cohort 2.  After  the approval of Amendment 31, no additional subjects will 
be enrolled at  18 mg/kg.    
 
Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/[ADDRESS_12076] of 24 mg/kg Sym004 treatment on PFS6 will be assessed in two cohorts 
with a maximum of 36 patients in Cohort 1 and 2 9 in Cohort 2.  With Amendment 31, the design of the 
study will be modified.  Within each cohort, either a two -stage minimax or two -stage optimal design will 
be used to assess PFS6 .15  The same benchmarks that were used with 18  mg/kg Sym004 are  used here 
with the same targeted type I and II error rates (i.e. α = β = 0.1) . 
 Patients originally treated at the 18 mg/kg dose level who have their dose escalated to 24 mg/kg will not 
be considered in these analyses.   
 
Non-Bevacizumab Failures (Cohort 1) :  A minimax two -stage design will test the hypothesis that the true 
PFS is 20% or less versus the alternative that the true PFS is 40% or greater . After testing the treatment on 
[ADDRESS_12077] stage, the trial will be terminated if 3 or fewer patients live 6 months or more 
progression -free.  Otherwise, additional patients will be accrued so a total of 36 patients will be treated.  If 
the total number of patients living 6 months or more progression- free is less than or equal to 10, then the 
treatment is rejected as not worthy  of further investigation in this patient population.  The expected 
sample size of 2 8.26 and the probability of early termination is  0.455.  The type I and II error rates are 
0.086 and 0.098, respectively .18   
 
Bevacizumab Failure (Cohort 2):  An optimal two-stage design will be used to  test the hypothesis that the 
true PFS is 3% or less versus the alternative th at the true PFS is 20% or greater . After testing the treatment 
on [ADDRESS_12078] stage, the trial will be terminated if 0 patients live 6 months or more 
progression -free.  Otherwise, the trial will continue and a total of 29 patients will be stud ied.  If 2 or more 
patients live 6 months or more progression -free the treatment will be considered worthy of further 
investigation.  The  expected sample size of 21.64 and the  probability of early termination is 0.561.  The 
type I error rate if 0.038 and the type II error rate is 0.10.18   
14 ADMINISTRATIVE AND ETHICAL CONSIDERATIONS  
14.1 Regulatory and Ethical Compliance  
This protocol was designed and will be conducted and reported in accordance with the International Conference on Harmonization (ICH) Harmonized Tripartite Guidelines for Good Clinical Practice, the Declaration of Helsinki, 
and applicable federal, state, and local regulations.  
14.[ADDRESS_12079] (IRB) and DCI Cancer Protocol Committee (CPC) for review.  The study may be initiated only after the Principal Investigator [INVESTIGATOR_12602].  
 The Principal Investigator [INVESTIGATOR_12603].  The CPC should be informed about any protocol 
amendments that potentially affect research design or data analysis (i.e. amendments affecting subject population, inclusion/ exclusion criteria, agent administration, statistical analysis, etc.).  
 The Principal Investigator [INVESTIGATOR_12604] -approval from the IRB within [ADDRESS_12080] be approved by [CONTACT_1201].  
 
Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/[ADDRESS_12081]’s st udy records, and a copy of the informed consent form will be provided to the subject.  
The Principal Investigator [INVESTIGATOR_12605]/her primary care physician about participation in the study.  I f the subject agrees to such notification, the Principal 
Investigator [INVESTIGATOR_12606]’s primary care physician about the subject’s participation in the clinical study.  
14.4 Study Documentation  
Study documentation includes , but is not limited to , source documents, case report forms (CRFs), monitoring 
logs, appointment schedules, study team correspondence with sponsors or regulatory bodies/committees, and regulatory documents that can be found in the DCI -mandated “Regulatory Binder ,” which includes , but is  not 
limited to , approved protocol  versions , approved informed consent forms, FDA Form 1572 s, and CAP and CLIA 
laboratory certifications.  
 Source documents are original records that contain source data, which is all information in original records of clinical findings, observations, or other activities in a clinical trial necessary for the reconstruction and evaluation 
of the trial.  Source documents include but are not limited to hospi[INVESTIGATOR_1097], clinical and office charts, 
laboratory notes, memoranda, su bjects’ diaries or evaluation checklists, pharmacy dispensing records, recorded 
data from automated instruments, copi[INVESTIGATOR_12607], microfiches, photographic negatives, microfilm or magnetic media, x -rays, subject files, and records kept at the 
pharmacy, at the laboratories and at medico -technical departments involved in the clinical trial.  DUHS utilizes 
Epic Maestro Care as an electronic health record.  When possible, the original record should be retained as the 
source document.  However, a photocopy is acceptable provided that it is a clear, legible, and an exact 
duplication of the original document.  
14.[ADDRESS_12082]’s data will be 
maintained.   Research Data Security Plans (RDSPs) will be approved by [CONTACT_12644].  
 
To protect privacy, every reasonable effort will be made to prevent undue access to subjects during the course of 
the study.  Prospective participants will be consented in an exam room where it is just the research staff, the 
patient and his family, if des ired. For all future visits, interactions with research staff (study doctor and study 
coordinators) regarding research activities will take place in a private exam room  in Duke Cancer Center Clinic [ADDRESS_12083] .  Access to 
electronic databases (without edit rights) will be limited to the PI, the study coordinator, and the statistical team.  
The only personnel with both access and edit rights to the electronic databases are the data management t eam, 
Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/2017  
 
PT-PhI-II v04.30.14  Duke Cancer Institute  Page 37 of 50 
CONFIDENTIAL  
 including the clinical trials manager.  The security and viability of the IT infrastructure will be managed by [CONTACT_12645]/or Duke Medicine.    
 
Upon completion of the study, research records will be archived and handled per DUHS HRPP policy , i.e. all  files 
and documents that relate to the protection of human research participants are retained for at least 6 years following study completion (see Section 14.8 below for other study document storage guidelines) .     
 
Subject names or identifiers will not be used in reports, presentations at scientific meetings, or publications in 
scientific journals.  
14.[ADDRESS_12084] 
research design or d ata analysis (i.e. amendments affecting subject population, inclusion/exclusion criteria, 
agent administration, etc.).  
14.8 Records Retention  
The Principal Investigator [INVESTIGATOR_12608] -related records  for the longer of a period of:  
• At least two years after the date on which a New Drug Application is approved by [CONTACT_1622] (if an IND is 
involved)  
• At least two years after formal withdrawal of the Duke IND associated with this protocol (if an IND is 
involved)  
• At least six years after study completion (Duke policy)  
  
Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/2017  
 
PT-PhI-II v04.30.14  Duke Cancer Institute  Page 38 of 50 
CONFIDENTIAL  
 15 REFERENCES  
 1. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant 
temozolomide for glioblastoma. N Engl J Med 352:987 -96, 2005 
 2. Reardon DA, Wen PY, Desjardins A, et al: Glioblastoma multiforme: an emerging paradigm of anti-
VEGF therapy. Expert Opin Biol Ther 8:541 -53, 2008 
 3. Cancer Genome Atlas Research N: Comprehensive genomic characterization defines human 
glioblastoma genes and core pathways. Nature 455:1061 -8, 2008  
 4. Jones -Bolin S, Zhao H, H unter K, et al: The effects of the oral, pan -VEGF -R kinase inhibitor CEP -7055 
and chemotherapy in orthotopic models of glioblastoma and colon carcinoma in mice. Mol Cancer Ther 5:1744 -53, 
2006  
 5. Dresemann G: Temozolomide in malignant glioma. Onco Targets  Ther 3:139- 46, 2010  
 6. Ohgaki H, Kleihues P: The definition of primary and secondary glioblastoma. Clin Cancer Res 19:764 -
72, 2013 
 7. Wong AJ, Bigner SH, Bigner DD, et al: Increased expression of the epi[INVESTIGATOR_12609]. Proc Natl Acad Sci U S A 84:6899 -903, 
1987  
 8. Sugawa N, Ekstrand AJ, James CD, et al: Identical splicing of aberrant epi[INVESTIGATOR_12610]. Proc Natl Acad Sci U S A 87:8602 -6, 
1990  
 9. Weitzner MA, Meyers CA, Gelke CK, et al: The Functional Assessment of Cancer Therapy (FACT) 
scale. Development of a brain subscale and revalidation of the general version (FACT -G) in patients with primary 
brain tumors. Cancer 75:1151- 61, 1995  
 10. Van Belle S, Paridaens R, Evers G, et al: Comparison of proposed diagnostic criteria with FACT -F and 
VAS for cancer -related fatigue: proposal for use as a screening tool. Support Care Cancer 13:246 -54, 2005  
 11. Beck AT, Steer RA, Ball R, et al: Comparison of Beck Depression Inventories - IA and -II in psychiatric 
outpatients. J Pers Assess 67:588- 97, [ADDRESS_12085], Reardon DA, et al: Updated response assessment criteria for high -grade 
gliomas: response assessment in neuro -oncology working group. J Clin Oncol 28:1963- 72, 2010  
 13. Ballman KV, Buckner JC, Brown PD, et al: The relationship between six -month progression -free 
survival and 12 -month overall survival end points for phase II tri als in patients with glioblastoma multiforme. Neuro 
Oncol 9:29- 38, 2007 
 14. Lamborn KR, Yung WKA, Chang SM, et al: Progression -free survival: An important end point in 
evaluating therapy for recurrent high- grade gliomas. Neuro Oncol 10:162- 170, 2008  
 15. Simon R: Optimal two -stage designs for phase II clinical trials. Control Clin Trials 10:1 -10, 1989 
 16. Wick W, Puduvalli VK, Chamberlain MC, et al: Phase III study of enzastaurin compared with 
lomustine in the treatment of recurrent intracranial glioblast oma. J Clin Oncol 28:1168- 74, 2010  
 17. Reardon DA, Herndon JE, Peters KB, et al: Bevacizumab continuation beyond initial bevacizumab 
progression among recurrent glioblastoma patients. British Journal of Cancer 107:1481 -1487, 2012  
 18. PASS 15 Power Analys is and Sample Size Software. Kaysville, Utah, [LOCATION_003], NCSS, LLC, 2017  
 
  
Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/2017  
 
PT-PhI-II v04.30.14  Duke Cancer Institute  Page 39 of 50 
CONFIDENTIAL  
 16 APPENDICES  
16.1 Appendix A  
 
 

Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/2017  
 
PT-PhI-II v04.30.14  Duke Cancer Institute  Page 40 of 50 
CONFIDENTIAL  
 16.2 Appendix B  
 
  
Name: [CONTACT_12649]- P rocedures for Provider Reading of M RIs and CTs  
Effective Date :  4/2012  
Review /Revision History:  
 
Definitions: 
MRI stands for mag netic resonance imaging w ith and/or without contra st 
CT stands for computed tomo graphy with and/or without contra st 
Radiation therapy (R T) mean s treatment of the patient’s tumo r with r adiation 
treatmen t, typi[INVESTIGATOR_12611] [ADDRESS_12086] enh ancement po ssibly due to anti-angiog enic thera py 
Non -enhanc ing di sease progr ession  mean s progression of the tumo r with c ompon ents that are 
non-enhancing on M RI 
Anti-a ngioge nic agents means a drug o r substance inhibiting the growth of bloo d vessels 
Seizure  means any epi[INVESTIGATOR_1865], caused by [CONTACT_12646] n, resu lting in the abr upt 
onset of tr ansient n eurolog ic symptoms 
Steroids  means a group of drug s that include s the cor ticosteroid s, similar to hormones p roduced by [CONTACT_12647] l 
glands  
Immuno therapy mean s treatment of d isease by i nd ucing, enh ancing, o r suppre ssing a n immune respon se 
FLAIR stands for fluid-a ttenuated inver sion recovery [image sequ ences] 
RANO stands for the Res ponse Asse ssment in Neuro-Oncology (RA NO) 1 
 
1. Dete rmine Patient Background Information  
A. Determine the pa tient’s med ical history.  
B. Ha s the pa tient had prio r surgery? 
C. Has the pa tient had Gliadel (carmu stine) wafers placed in to the rese ction cavity? Note: Be ca reful with 
therapeutic effe ct 
D. Has the pa tient undergone radiation therapy or s tereotactic radiosu rgery? 
Note: Be carefu l with pseudoprogression 
E. Ha s the pa tient taken any anti-angiog enic agents, such as beva cizum ab (Ava stin), s unitinib (Sut ent), or 
cediranib (Rec entin)? Note: Be ca reful with pseu doresp onse and n on-enhancing d isease progression 
F.  Has the pa tient experienced seizure a ctivity recently? 
G. Has the pa tient tape red up o r down in their dose of steroid s? H.  Has the pa tient 
undergone any for m of immunot herapy? 
 
2. Pi[INVESTIGATOR_12612]/CT to which you wa nt to comp are the new MRI  
A. Fo r high grade pa tients off  therapy, go back to the M RI when they stopped 
therapy. 
B. Fo r low gr ade pa tients off therapy, go ba ck to  baseline M RI. The best baseline M RI  is normal ly 2-

Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/[ADDRESS_12087]-operative (post-operative changes mu st have resolved and at the nad ir of cav ity 
collapse). 
C. For patients on t reatment, com pare to baseline (response) and to nadir 
(pro gression). 
 
3. Look at T1 pre-con trast images/non cont rasted images 
A. Is there new bloo d? 
B. Are there ca lcifications? 
 
4. Look at T2 and /FLAIR images (No te: my preference is for FLAIR images)/non contras ted images 
A. Mo st freq uently, we loo k at axia l FLAIR image s. 
B. Determine RA N O – T2 /FLAIR lesion resp onse. 
C. Be ca reful with incr ease T2 /FLAIR from tumo r progression v s. treatment effect. Is there incr eased 
mass effec t? Is there at rophy? Is it in the radiation field? 
 

Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/2017  
 
PT-PhI-II v04.30.14  Duke Cancer Institute  Page 42 of 50 
CONFIDENTIAL  
  
FLAIR T2 
 
Response Definition 
Improved Signal abnormality decreased 
Unchanged Unchanged compared to prior imaging 
Worse Unequivocal worsening/progression of signal abnormality (due to tumor - make 
sure th is is no t due to infec tion, infar ction, demye lination, radiation) 
Unable to Assess (UA) Unable to evaluate non-enhancing lesions because of technical factors 
 
5. Post cont rast T1- weighted images/post cont rast images 
A. Look at two planes : Axial, Coronal, Sagittal. 
B. Ma ke sure you are l ooking at the po st cont rast scans. Is the nasal mucos a white (post 
contra st) or the same grey shade as the bra in parenchym a (non contrast ed)? 

Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/[ADDRESS_12088] 

Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/[ADDRESS_12089] the fo llowing cr iteria: 
v.  Contrast enhancing 
vi.  Clearly defined, bi-dim ensionally measurable margins  
vii.  Two perpendicular diameter s ≥10mm 
viii .  If slice  thickness + gap is >5mm, size thres hold is [ADDRESS_12090], or necroti c area 
E. N on-measu rable lesions meet the fo llowing cr iteria: 
x.  Less than 1 cm in any diamete r (e.g. 12 x 8 mm) 
xi.  Poorly defined ma rgin 
xii.  Hemo rrhagic or predominan tly necrotic 
xiii.  Tumor ar ound a cy st or surgical cavity, unless nodula r comp onent 
≥ 10 x 10 mm 
F.  Choosing ta rget le sions: 
xiv.  If there is more than o ne, pi[INVESTIGATOR_12613] 5.  
xv.  Choose the la rgest lesions. 
xvi .  Shou ld have r eproducible measurem ent. 

Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/2017  
 
PT-PhI-II v04.30.14  Duke Cancer Institute  Page 45 of 50 
CONFIDENTIAL  
  
 

Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/2017  
 
PT-PhI-II v04.30.14  Duke Cancer Institute  Page 44 of 50 
CONFIDENTIAL  
  
G.  Determine RA NO – Target le sion m easure ment/resp onse 
i.  Axia l plan is recom mended, unle ss patient ha s been fo llowed in coronals 
ii.  Pi[INVESTIGATOR_12614].  Measure the longe st diamete r (A) 
iv.  Nex t, measure the greatest perpendicula r diamete r (B) 
v.  Calculate the ta rget lesion size - pr oduct of the diameter s (AXB) 
vi.  With mu ltiple ta rget lesi ons, calcula te the su m of the pr oduct of th e diameter s 
(SPD) = A rea001 + Area 002 
vii.   Follow-up eval uation: 
a.  Measure the previ ously defined ta rget le sions bi-dimen sionally 
and calculate the SPD (Note: CR and PR have to be confirmed ≥4 
weeks l ater; ot herwise, it’s just SD) 
b.  If apparent PD within 12 w eeks of radiation, k eep wa tching. I f SPD stable or 
decreased on next v isit, drop base line value w hen pi[INVESTIGATOR_12615] “nadir” to compare 
again st. 
c.  Are there new le sions? 
 
H. RANO – Enhan cing non-ta rget le sion respons e  
i.  All non-measurable  lesions 
ii.  All measur able le sions beyond upper limit of 5 
iii.  All  other measu rable lesions not selected a s target le sion 
 
Response Definition 
Complete Response (CR) All target le sions have complete ly disappeared. (look out for 
pseu doresponse) 
Partial Response (PR) SPD decreased by ≥ 50% f rom base line val ue 
(look out for pseu doresponse) 
Stable  Disease (SD) SPD < 50% decrease to < 25% increase 
Progressive Disease (PD) SPD increased by ≥ 25% fro m nadir value 
(sma llest seen during the tria l) (look out 
for pseu doprogression) 
Unable to Assess (UA) One or more of the target lesions cannot be evaluated 
because of tec hnical fa ctors 
iv.  Assessed s ubjectively 
 
Response Definition 
 
Comple te Response (CR) All enhancing non-target lesions have disappeared 
completely 
Incomplete Response /Stable Disease (IR/SD) Enhancing lesions present, and stable or de creased in size 
com pared to prio r imagi ng 
Progressive Disease (PD) Unequivocal progression of enhancing lesions (see below) 
Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/2017  
 
PT-PhI-II v04.30.14  Duke Cancer Institute  Page 45 of 50 
CONFIDENTIAL  
 Unable to Assess (UA) Unable to evaluate enhancing lesions because of technical 
factors 
I. Ps eudoresp onse 
i.  Anti-angiog enic drug e ffects can loo k like  response  
ii.  Appa rent respon se may appea r within 4 w eeks 
iii.  This should be c onfirmed w ith follow-up imaging 4 + weeks l ater 
J.  Pseudoprogression 
i.  Enhancement t hat looks like  tumo r growth but isn’t  
ii.  Radiation e ffect can loo k like  tum or 
iii.  Appa rent PD within 12 w eeks of RT 
iv.  Call it pseu doprogression (psP D) initially v.  Re-
eval uate at next imaging visit 
vi.  If furt her increase, ca ll it PD on the fir st visit vii.  If 
stable or decreased, psP D is c onfirm ed 
viii.  Do not consider base line fo r choosing nad ir – looki ng for 
progression 
ix.  St
ill use base line w hen looki ng fo r resp onse x.  New 
lesions 
xi.  PD within the 12 w eeks of comple tion of chemo radiation can only 
be a ssigned if: 
a.  Major ity of the new en hancem ent is outside of the r adiation fie ld 
OR 
b.  Patholog ic confi rmation of pro gressive disease (tricky) 
c.  Lesion c ontinues to enlarge 
 
Baseline Visit 1 (8 weeks) Visit 2 (16 weeks)  Visit 3 (24 weeks)  
100 140 
psPD  120 
SD 150 → PD 
130 → SD 
65 → SD 
45 → PR 
K. RA NO – From le sion to timepoint (radiologica l) 
 
Target 
Lesions  Enhancing No n- Target 
Lesions  FLAIR/T2  
Lesions  New Lesions Radiologi cal 
Timepoint 
Response 
 
CR  
CR  
Not worse  
No  
CR 
 
CR  
IR/SD or  UA  
Not worse  
No  
PR 
 
PR  
Any non-PD or  UA  
Not worse  
No  
PR 
Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/2017  
 
PT-PhI-II v04.30.14  Duke Cancer Institute  Page 46 of 50 
CONFIDENTIAL  
  
SD  
Any non-PD or  UA  
Not worse  
No  
SD 
 
UA  
Any non-PD  
Not worse  
No  
UA 
 
PD  
Any  
Any  
Yes/No   
PD 
 
Any  
PD  
Any  
Yes/No   
PD 
 
Any  
Any  
Any  
Y es  
PD 
 
Any  
Any  
Worse  
Yes/No   
PD 
 
NA*  
CR  
Not worse  
No  
CR 
 
NA*  
SD  
Not worse  
No  
SD 
 
NA*  
NA**  
Not worse  
No  
No Ch ange 
NA* = No ta rget lesions identified a t baselin e. 
NA** = No non-ta rget lesions  identified a t baseline 
L.  RANO – Radiolog ical and clinical factors 
 
Overall Visit 
Response Definition 
CR • CR by M RI 
• No steroids above physiolog ical levels 
• Clinical status stable  or improved compared to baseline 
PR • PR by M RI 
• Stero id dose not inc reased com pared to baseline 
• Clinical status stable  or improved compared to baseline 
SD • SD by M RI 
• Stero id dose not inc reased com pared to baseline 
• Clinical status stable  or improved compared to baseline 
Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/2017  
 
PT-PhI-II v04.30.14  Duke Cancer Institute  Page 47 of 50 
CONFIDENTIAL  
 PD • PD by M RI 
• Stero id dose stable or hig her compared to visit at wh ich best MRI 
response wa s seen  
• Clinical status wors ened com pared to eit her base line or the v isit which 
showed the best MRI response, and n ot attributable  to a non tumor-
related cau se 
NC • NC by M RI (possible only if no v isible tumo r at baseline) 
• Stero id dose not inc reased com pared to baseline 
• Clinical status stable  or improved compared to baseline 
UA • UA by M RI 
• Stero id dose not inc reased com pared to baseline 
• Clinical status stable  or improved compared to baseline 
M. RA NO response cr iteria 
 

Pro000 [ZIP_CODE]:  Ph.2 Sym004 for Recurrent GBM  
Version:  07/5/2017  
 
PT-PhI-II v04.30.14  Duke Cancer Institute  Page 48 of 50 
CONFIDENTIAL  
  
N. Additional info to he lp 
i.  Split lesion: m easure a ll and add them  togeth er  
ii.  Me rge: m easure the b ig thing 
iii.  If CR by M RI but still on steroids : PR 
iv.  If PR by M RI but steroid s up : SD 
v.  SD by M RI with  steroid s up (but neurolog ical exam OK): SD fo r now  
a.  If next visit shows either neurolog ic or MRI wors ening, ca ll PD 
when the steroid s were incr eased. 
vi.  For patients with non-m easurable disease only at baseline: 
a.  Cannot have a CR or PR. 
b.  Best respo nse po ssible is SD. 
 
Referen ce 
 
1.  Wen PY, Macdo nald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galan is E, DeGroot J, Wick W, Gilbert 
MR, Lassman AB, Tsien C, Mikkelsen T, Wong E T, Chamberlain MC, Stupp R, Lam born KR, Vogelbaum MA, 
van den B ent MJ, Chang S M. U pdated respon se assessment cr iteria for high- grade glioma s: Response 
Assessment in Neuro-Oncology Working Gr oup. 28(11):1963-72; 20 10. 
 
